var title_f4_12_4288="Meibomian gland dysfunction - cicatricial";
var content_f4_12_4288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Meibomian gland dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 304px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEwAdsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDz6L0q0lRotTqK5zYUCn4opVpgGKei01etTLQQKoqTHvQop2KhlIhcVSuBirzjiqVyODSNEZdyRz61k3jD5sVoXcvWsS7bNNFFK4bmq55qV+TSYrVENkeKMVLikxVkkOKMVNgUYoIIcUYqbFGKYEGKMVJijFADFFKoqRRTlFACYoxTsU7FMkjxRTmFIwpAKhIq3CeaprViE1mzemzTgq9H0rNtzWhG1Ys1LSipFFRIakVqViS3DgYqbcKorLUqEk0LQT1LBOaAM0IKnRatMyZBtJprrV1hxVabFWyUVGqFzU0xqo7VKLYxyDULGh2qEt71YCOarSmpHaqrnmk2aRQ7NGahzQTUItoRzVRzUzmoGrQxI2NManNTaAEpmKkxRigCPFGKkxRigCPFJipcU7bQBDikx7VPil8o+lK5SR6QgqVaiWplpEEoFL5VAan5FBAzbilWnd6ctSyxy0uaTBoapKRG54rPvGwKuXB4rIvJeDUlIyrxutY855q9eN1rLc5NaJFMjxRinLTq0OdkeKMVJijFWIjxRipsUYoAhxRipsUYpkkOKMVNim4oAYop6inqKlVaYESrS+XU6rT/AC6Yioy01hVpo6gdaAK+Kmh+9TSKE61m0aJl+GrsRqjAauxVizcsA08E0xBmrEcdQ2Ow+EZNXoIvakgQVaXAWpvcGKgxTi+KrvLiqz3A9a1Rm0XHmx3qnNOBVSW496qzTE1oSWLieqTvzULymq5lNOwyw0tRNL71BuzSZpFWJXbNV2NKzVExpMtaBmgtTM01qQNgxqNqVqTFUZDabipMUuKAIsUuKkxTlWi47EOKftqZYiasQ2TN2qG7Fqk3sUgtSpAT0FbFvpZPUVpw6aoHSsp1kjrp4Vvc5+CxJ61eFkMdK2vseB0pwhixXO61zqjh0i8tLSLT67Lnijd1KppNtPVadwJENWEFRItWkFSxITFQy8Cp2xVa4bFIop3bYzWLeN1rTu2rIuTmmi0Y911qk3Wr1z96qTD5qsGIop2KVRRiqMwxRilxxT8VZAzFPxT1FKooJI8UbanxRtpgQYoVan205VpgRBalSOpgtWY4c0CK6R1MsBPatO2sy3QVtWug3Ew4Q/lRzAce0B9Kryw13Vz4ZugMmEgfSsW90xoc5UincDlJlxUKjmtW5gwSKotHzSZaHwVdjPFUkFW0rGZui8hq5ARis1WqxHLXO0bGsjcUGYVSSb3oeTimkQxZ5qoPIcU+RqrO1aozYrSVC7UjGoWNWKwMaiY0rGo2NO5VhWNRsaGpKQwzTKdijFSIZSYqTbSqtAWIsUeXVlYyfu1PDZu3RaTlYtU2yjtpyx1uW2jTSfeFasGggdaxeIijaGFkzlo7Vm6Cr1tpEjdRXX22kKoBxV1LQYwBzXNPFdjsp4JLc5e20cDqK0ksFUdK6FLUMOnNPW0+TGKwdVs6VTijDjt9tWlt1I5FW3tipqRYMrSHoUPspBx2oNkpNakMWeKf5BpK5LZziD2qamLT1r1LngWFXrUq1GoqZRTuRYVakBwKaBT1U0MpETmq0x4q661TlXipKMu5NZdz3rXuRWTcjrVoZk3NVKuXI5qm1WJirT6YtPqiBcUL1oWlXrVkEqinKKRalWgkMUYp9LigCPFPVaXFSKKYDo05rZsLXzSABWZbLzXZ+FLP7ReRL6mom7IDtfA3gwXSie4H7uvU7HQLW3iASFPyqfw9Yra2MUYHatwAemfpWEHfVmnIZE2j27LhoIz+FcX4s8D215BI1qgEtelSQCVdrggcHg4pk8OQa2UxOB8geJtDm0+5Mci4INcrcRYOMV9M/FTQI57E3Ma/vF6187apDtmNaCiZKip1oPFNzWbN0PzUitVRjRuNZ2LL6S09pM1SWWnB6QWJWaoXNKxqJqdw5BjGo2NOIpuKdwsMakqTy6csJPQUrj5SHFG2r0VjNL0U1o22gXEvJXFQ6qRoqMnsjB205ICegrsrfwwQAX5rUt9DhiGRHmsXiorY6IYGT3OFt9Nml6RmtWz0Bm5cYruLSzj6Koq4unAciud4pvY6oYKK3OPg0ONCOM1q2+mxjgKBXRrY9yMGmJBltpHFYuo2dCpxWxmpYhe1TfZAOK0vL8scDI9KXyfMwUqBmSqmNsYyKm8g43IK1HtBKMjrRbRY+UjkUWJuU4FDYOOe9PmXyjntVpIws2BUky1SRDZlOobmkhXnFXGhw/FMMWJAaslkKRYlIp/l1I33wfWpRHxVpGbZxiipFHtTFNS7q6jyB2KVTiovMoLVSQmTA1IJRVPdTfMwa0ILzSiqsxFM3VG54qSyvcisq6FaFw1Z8/NCLMe6FUGrUuRWe4+atUQyNafUfelqzMkp6moVp6mrAmU1IpqBTUqmgmxMpp61CHqRTQFianxVApqRTQFi/aDmvQ/AAH9owfWvObaTBrv/AIfSj+14N2Otc9Z+6xpH0hpyjyY84+ma0U9FrO00AQjpV5T/AHaiGxoS1HNSqaglYDvVgc94vhE2j3YP92vlXxDGBdSD3r6Z8fa1b2GlTh3G9hgCvmPWJvPuZG9TW17IShdmGRUbVaKZpPJJ6CsWzdUypikxWgmnzy9Ij+VXINBuZf4cfWodZLqbrDyeyMTBpwBrqrfwu3/LRsCtS38L24I35NZPExRqsLJnDLET2qVLORuimvSrfw/brjZGhPvVkaZGBwAMdqxeK7I2WC7s83h0W5k/5ZkfWtC28LTN98gV3qWoI2kfQ1JFa7X2ms3iZdDdYKKOOh8KouN5JrStvD9vF92P8TXTsEiwpHJpz2xPGMVg6sn1NFRiuhkR6WI8DaB+FWPsgjK5HHrWvHbn+PmpDGc7JF4xTLM+FBG3zDIpcKWO1eKsLD5LFcEjtT7WIuxPSkPzKlnAolIxmtDyMDpx7UrW+DuAwauW53LyKpIxmyn5Qx3K1VubcNynBrYcKOcVCYw3OOaTEmZaLvGOkgpttuWXa4GO1XZYMEMnUdaruCZ4xjFJou9yfYR9yoMH7RgjGa0VTiqt5GdwI6irRjcjtoMzHcc1a8gHtTrJMjcepq5t+atEiJvUotaDFUrm2KA4FdAipuHmA7Pas6827iB0zxmtEjJVGY1vESfnHSrgiGKdgK9PyKEhyZ5uGpfMqWC0Mn8QNEtk61sqqOWWGkiHdRupuxuwppDD7wNaKojB0mt0SM1NY1BvNLup3F7MsKaCag3UjSVLGkRzj3qhcD0q1M+aqTc0kXYoXAzWfMtajiq00VbJkumZpFJirbRUzYaq5k6ZBin4qfyye1KIGPaq5g9mQLT1qwts56KakFjOfuofyqfaItUn2Ky1ItXE0y5bpCasJo10f4MVLrR7lLDyfQz1py1sweHbpxnFXrfwvMx65rN4mmupusFUfQwoTg1uaNqMlpOkiHBBrRTwqIkBk3nPpV+z8PQh+hNZvExaNFgZHp3hP4hJNDHDdI5IGMgZruLPxFDdJmBJT9RivGrC1NouYPlx1xWvDNOB/r5Nv1rnWItsN4DzPVJ9UKRZkaKP6tXM6vr4lG1NREf+6uTXJ/NL/F8/vUUkGRg1TxLLhgI9WYPiexfULgsl3NKD3YVzieGg0p3sTXbQDcCHPQ44ptvGsFyVfPNZvESZ1Qw1NdDnIfDduowIt5qxDo0EfBhAPriuqWFFcEDINVr1WhAKcpnvWTbfU1gl2MJLSOF+gx71cTTgw3BSM9Kt30amzMi81NaTgRxjkZHBqTbpoZ/2I5+7ggdPWrVtCsqe9OlWaOYF5Mof0qCePypsuCgfqR0qbBa5agixLg9RTri3zyODTrIFmy3OOM+tabW2DzyD0oRDdmYrQE4kVeRTzamYCQHDirmww3Bz0NPRPnkUVQXKH2f7Qg5xIKmsxI3mRv8AfHQ+tPiG25K7T61PHgX3HpQDKi+ck2xxx2q4FeY8DgVPPCJULelGnhvKye/enYzb0uULtfJw4/EUZCvuQdua07q381M96p3ChSORmTgCglNWFXkAnjNSWwHO2nMo8qP0qaGLyhwOKtEzZE0eelSJCo4NT471e0zTnvXxGoOOuadtTJz5UYtzFgkVQwBOMj8a2b2Aw3EkT9QccVmyAb+lU0VB3RKq596juF4qxGvAqW5gaEAOOSMimkZ31KVkf3X0q7bsqyxmYZGeRVGIYJFTLTRMzsopdBa1yQAcdD1ridSEZuD5AOzPFOcHIKGnMmRWm+hkkoalGSLcOKrFSDjFabrVfZ7VpYdzibSLPzY61eVeNpzinrFgcCpYY2bJYAJ0HrXMkdLZTls1HIHWm/YtwUoyZ7jHNalwCRgDpUKwkdKbGmZx04EZ/pTP7OUjkDP0rcYhhhxVfydw47VndlpJ9DL/ALOhPAVM1F/Zan78ODWy+VIJznPBqaUzMA4JJFF2P2Uexz/9hQzZ8sZqB/DYIPDj2zXS2ZaS5LKMeprT8vKn1oU33E6UV0OA/wCEfj6fOPrQPDtuxxmu2FocFdoI7ZpYbRSOV5HWhzl3KUKfY4b/AIRqBmO3JxUv/CN246Ln1BrvYYIRw6VFNY+dN+7x+VP2ku5Sp0+xx39i2sRTEOc1Y/seEHPkhAK7FNIJXpnFSRWQXg4yemRUajTprY5G10yNkOYOPXFWzpABG9BjsRXTC3aLjjYe2KRx/DOo8vtjtUWHzmCmjkDeioR6Zqx/ZySrhvk/oa0Npt5eP9UfWi5SRsSIOvJ96C7ldLUeVt2ASDvUSNAHI4E4HHbNXvK/epcDPTBFSXtlHJEs8a5cdcUkGhHbqrAFuh6iiW28h9wHFW7dPOhAA4qzGpH7t+RVGbdjKuVJyYzzjpUtjhl9far/ANlG/HQ9qz3/ANFuTxtBNKw07kj/AOjNz0qd7uHyQMBy/QDmpfKW7iI/nVfToVtpjGy854NHmToyvbwt5xwhCH1qee0MwBTiUdK1vkbr1qGT93yBnmnYlTbM+3O47LgBJBV5oRLEVfFTGJTyQNr06CH91ilYTZhTWXlgrglDS21v5lt8o5j6V0AtTjkcVF9nEJ3IOD1FFi/bXMi5RTaZPGKZbwG5tsHkY4rSmhHnEf8ALNqdYxlcw9cdKLFe00M7Sk+UwOOVrWtl+Xk9KqPARqAKcZHNaKAeVgVSWplUdyKaATJ0rLELLdFscfzrXhGDU3lKe1PcSnYxlUG6ByeR0p9zEI7mJsdOKvXUOMEDGKr3gysTehp2KTuRRRTTA7GCD6VctYNsOPzp9rFtySKtWw3JzxTSMpzIdh4GOKoXNoDdRSf3MkVqkc1DcK3OB+NFiUzPY7R83rUnmkuBxiql9ksPc1Zt1yee1I1aVrk8xHFX7L7WsTvb+ao7kU2ysTeThEHPeu4trNbPTyhxjHNawg5s4q1VQVjzW8kOTtG+Q1VSFmfc/Fal5GBNIQO9UoQx3E1TWpsnoaMWmH+z47tDkE4I9KhvFwoXaQe5NXNKnaLEJkxATk56VLqU0d3Li3j5HU+tWkrHM2+Y5xkw+aGJHSrU0PNN8nvRY050NA+XNaGgW8NxdAXSkxVTETA8itSEyaegYng8jitLGU2XdU02wtYgckE5K1zeyLupz9auapd+cRmTPsO1ZRxnqa0uZRTW5zEPp1q/BHlAD1qCGPAxVkHy+vSuJI9BieSO1J5eDipkIIzSPH/FiqBFR05NT2cSk5fpQimUngjFS28J3Y6Vi0aXHXlpkAop8tuhxVOGJl68itpt/lCIsSg6AnpVZ4to6dKp6ocGVLa1KD5OM9aueXtFOtipOAcmrO0Hj+KoG2RImRwtQPCQc46VoIuPpSyKMUILmevIHPNXoIsJk9agt4Asx6+1XwuE5otqE2Otiy5w2MjFRvDzUyDBqxjcAaa7GTepRMOUwfwNV9hJ2uBn+da20Aciqc1vvOUPIoaNITKph2qY5AcHpViCPam3Gfan9YisgxirNpGHQECsrDb0KX2byTkD92etMhGJfLTp2rY8gkVC9vgZHWr5BKr3KCQhJyB+VPMM32qJgwEY6gjrQkDGUtu+cdauomaaQTZE4zz0Iqvd2onB960Ui556Uy4gwdw79DTsSp2MK2ZoLiKN+vQ5q/egZib3603UYQY9yj505GKdbZu/LIHEfrStY0vfUmC5GamEO4cjPpUu3BzirsO0oMcAihQMXMpKmBgjii3XGRV1YSxwgJ+lPsrdJrgJcHC5wTWljP2hGhXneCeOMUxLcy5CgmuifQRkbDkdjmr0FlDYxb3AJrVUZbHO8QuhwN5AyREYww9aggYZd2wAO5rc8W3kJlj+zxgsePSuetLEtkzHofu1nVhZ6HdSd6d2Kim6ufO6RDp71oCLA24oSMjAA2D2qwi4OMVKRM5lJ7c798ZxJjHPQ1ciU7RvGDjpUgAPSlYY5p2MrlO5GVOO1UgNxCv61oTY5B4JrHuZTb3I7g0mb0tdDRY4DVPbDEVU0g875gTnGc1oQBlTDjkU0Zz2BhxULLhe57c96nXOaD0NWZmHqMJB45zSwHbgP1q48Zll9hSy2ueQeaOTU359LMu6Xcm0nEyHp1rV1XXGmXZBgx+ornkSQcN0qULWqVjmmk3cgfLGo9uK0IrVpm+RST7VMbRQAZGAzTSE6i2KkELM4CAn6V0FtZwQH922SRzuFVIJvs64tenqwqwgmnQFRnP3mq0jmm2yjc2QjyzlM5zgHmobjBWRhbhARwasSWrebyAOe9WvsJmiL5RADge9PqTcy/s/lWvnuefQ1XvblpUSEvvjA44pb4yb9kjZx6VQcHPzCgtFR8bvnBx3qA4zVm4BX8arfjSNDJQEe9PPzVJHHkZpjsAcc1zo6iRBge1L50YGDSoCwxijyCDmkWiW2UO+QCBirPl4HvUEAYdTxVtGDfdpAwxjqKi27u3WrjD5KRIRuyCc1Nh3KPkbeQKt2o835iBmpHi3ZxipbWA9eRSaG56DvLpyqCKnC896ZINtUkRcpNCGmGOCKsAEEA+tIkBVOG/OnANj5+lSyycQ5xj8alReOKSMg4xU44qkYMhZc8Ck8nnNPLYl+tSqM96T1HdorSwArUloMADtVryxiqruImxz+VFgUr6FzPFEyxeUCCST1HpTEPOa0bq8tntVjijCkcE1pSSvqZO5zxUC5PHX9anQDPbBptwuSCMZFHI5/h9Kh7nRuiZIHmmEMAG88c1M8E1tKDdQB8dieKqxzsrA/lVme7e68vexOKqFupi07mfOoJPy9fSq+mYimkh4BrRcKUxWdbQ5ujJ/Woa6nRT2Zv2NqbhwoHWtS50UwQjYc4FY+m3xsp2Kc47VqnxAdhJXINa0uXqcVVVL6EWm5tboZPXg5purwiC5cgAZ5rK/tHzrgYJHPermr6kk6A9DjFWnFXQ/ZSumX7PWmhg2sA+O9V7zUpps9AD71jgrsY5o80TRSBe1Qpu2hfsVe5QuZhPqGOoWr9ouQW9ay7OFDLIx65rYt2UL1x6VklqdVTRWRctLRpyABk1oXmkfZ4w4Oag0y/8AszZwCKnv9SNzjZxHW8Eupwz57mcRz0pkw7danyCammiJGCvI9Km1wvYy5oC3bNZ11Y7nyc4zXWaSyx3I3gEdOa1L/T4LpCUIyBzimqVx/WXBnP6dpBMURTqR0roV0m2+zgFcMByaTR4GgQqCHA6HHNaExAU84x1zWsKSRy1KrbMD+xVkRzv2kdKzIIkYywvjOOD71YvZbnzyY2PlnjNUUUp1HPqaU0k9EdFO9tWVHhw5FW4LSaaLco4FSphH3Fc+xqc3bE4hURD0FJIbm+gJpqtgyTog/lVS4hhhuPkJdBU7ZZ+59abcr5PylcE/pV2Mru45rzJP2ZBFkY4601of3QGMl+vtU1pbwyiTfyAM5qFpyvmiCPr39KZHoWGh5hXcAh7DvUN5dsoMAbZEnpUDq6pG7sQe2etV3845uHIftzQUkWLa9Kj7hkJGFJqJb0zmKC4PlxqecVXSUx/vAdjr0GKg8uS4csgJPekOyJdSUrcnDbz61VmX5ckpkUMNv3s5pbiIxW4d8c9BTAp3LhogAoGO9UDnPSrU0pCbc8GqZznv+dJmqJGhC8Z/TpUrWKnZjJkIzyKktIgCHeTHB96m/wCWSBeSF69MVFi7lT7OV6jGRTGAYlRyyda00LAAjDZGAKjhUSMc8Y6ZqLDTKDQkginW6mMY/hq+0K5yOh6U4QEoW61Lgae0KrnOMdKkt8hORzTvsknU9vSpkjIosPnVhqAEbqlgfBoEXXNPTBNOwrkq/fomAxk8AetAQnmnuuRgjNFiLlXKYzUbxZ+XGQfWrewdMVGVyePvVNi0wXauDzkCpPNPlZpjKSKc0RPFCQcyKkEjTSkHPHSriGaM+oqdIQOQMcUOREMk0coOdyXzdxA9e1XdYsbeFAUP7zAyKz7cqJkZ+gOat6xdRXNyTBkgitaNtbmTTurGbkjGTxR5pA6596Y5yoAHNG0r+NZG5IncE0x2+T/Go0ySee9Sf8tNuOKdhCgDbz+tNBIwycg05MNkNwRQV8qIpjilYYk4PkkjggVTs2aLlx8h7+laa/MmMVCkPJU9Kdrgp6WJGXncFqZTlM8inRDK49KdgCmkZNkFxCCM9xVO5g3fNk5PatGXAB461EvK9KdioTaKqwjZgmpXBTBT8aauRMRjj1qYqQc5z7UrDuUXtyp85OM1YtreaaHcc/hVtIlMRyDkniug026tYdPwyhGx3FNQuROu0jnIVKfIe1Wl9TS3A8yYsCBmo4VPA9uau1mZt3CEbs7K6C3t91vE5XZJ/OqWnWhkG7oK1PMjiQjdwOnNaQgc1Sd9iGa0XH3Qkid/Wr9s2Mb4NjYxkCqrzxmLzAB+eBVR7xwMBs/0q9CNWbFsBbhy5465qvfXqmIjsetZiSzS43lyg4wD1qB2+eTb0zxkUrjUBr3ByQnyDsKrTnJVSST/ACqVyS3qTUcS7ph7HmoZqhzQlcKRzTkgAlUycAjvV2XIJmcDgcDFPto8x7nJJPNOwuYjMNuqDc6Y9B1rNMJeXg5+tWJl8qfJYPio7mUyEsRgewpkIjlmJ+ToPbvUP8eQAKliaLnepPHFP+yAwlt6ADnrQXexXvJXJG988cAHpVNQ0nyoCfpVy3jSTem4A9iTxVTbMGIj6gc4pAiIsTw/yYpYoppBJ9nB2dyKQrkbnPBqBbloY3VMgH0oNBQc/f7VHqV1bskUcAkyByWoYwSWxOdkg9+tZc2A3zH8qQJCXDYqvuH96kuCSW5qpUl2NvyiyL5anHQmrDQkODIc5GarpPcXEu9+uOAOgFSwgSHM7E5PUDpSAVbhjlQuATzirFq8JuMlSIs8qT/Wi1iYrKCUQR8kEcmpIIQwyMgE9MZp2C6HIizTfuMkehrSuLcLD8iBPlBYVHZ+Wt0VhA+Zu46VYd2ETqSMyScn0qktSGyv9jzbBhnfjPWrS6Zuto2IIPUk+lWAuFnj3fOBxx1zUcO+fCqzgRjuadjPnZQezIyUy8Y74pWsWjtvPfAStu2haXh+gFWUKiE/LgrnFPkTH7VnNeX5QXkc+la9ppvnWJyiF3GVJPSo7a2b7cCc4f8AUVtXoH2cKpx6A9hRCC5hTqnIzQ+W5zUCL+96HFb9zarNsI4yPzpn9hzqxIaMgDPBpThroaqsramN5R5X171L5LDqMitO2s5hJu8neB696BJHFvV4c5HHtUez7j9rfYosCR8tRN8x5q+YowQd+Q4zgDoaqmL97x0pNDTExgVWm/dcgfhVp+DzSNA00RxjPvUWLuU8BznHNB/eECp47SYAHaQPzq0unEFDIdmaqzG6iKMUJw+Bg+9O2574IretrMMnJHTOaItNjPmEt09qr2TMvbIxGj+YH86V4yRg52n0rUubAxPgHIPIqMwts5B+tHs2g9qmU0HYUnkF3yAfwqVIW7itS0t5rX95IpAYcEGhJg6tjOWM4HBHsaRoSQMit+3EMw/eJgg84pk1vCokwp655Nacpl7cwWty2Opx1pr2kig5UpnpW88ymLywUjj7gDrSQmHGLhuMcUuVB7VmALZiMIMv7VYtLKaU42kEe1bW8QtuhhTjoaqT3E6YycE88HOaOUv2rZEulzng4TB5yakSwwCHni4prTPKI/333+vt9ajeOYZ3/UMOhp2RN33JPs0P/PYfQCpoUhA+RQZfeo0h+cL1z3FWFVsAxgAp2PeixDY0zmMYJIz1qu0xz8gwh7HmrnlEgnH7wnOPWqvnFSuO3YihkxIlhZoiSfudu9NEUkx/dgkDrUj85Jzz1560zzZRFt8wgegpFjkfy4ypAOf0pg5xlfpUqiILg5H9alhhN1kdMdKCbkW3DgQ8uD1pwiMLln3h89RVsWw5x8/bNSLkIiuFxnOaqxPOUPs7TAsTznv3qRI5llKxjJq9LKDmRCOnpUTsYhyOe2O9FhXZU8gKf36nOKasMIwZxnPQUtxK0vzFSMd88VnTz7u+TTGkxblTBKQhwfTOcVUuecL5gOaPNwDzzULSnPIqDVE1tDGcEzY7mo7qaEufLJx796sefbS2+2fehA4wKyuOf0oBbjJ3GcJ096rueOaknBixkjn3qs54qDREDEE8Hj3qK6lTjyyTnrSkZPJxUcVuj5/egEetK5RSZuaNwqK5+VmGc+9M800kUblirYuAQCUXox6VckhZUizl84xVKG3BJj3ASD9a1FExSIZwMdKaJYQ/NCeMEnGT1qxbki327sDNV8RrIQ5II7AZqS0Cu4yT5Y5NMkuQQ4Y7XHBxuq0AJBEuOp7HvTkiUSJJjdkfKc9DVpYRsfAwR/FjPSrSMmyvaLcGYSBgHzg5q4ICqyc5Ldx6UWuDagEgZHUU25lmEUYkYGLsQKaIuTJdsDuABAyCvfFS2U6TfNhzngZ6CoUPnXA8tOMc57GiOB7dvLCPhjyc8VQaE77lAwpDg9fSpccbgxf5enoaYszkYfIjxjpU8EqHp/rOhpkDTKsqwdQB2qZJiVJxwOuBTYkBbD5yKc6nODgY6+9AhWmBG3jjoRUM0MD7ztFQXhKh8YEZ7DtT7Zt0OSuQOhNDZVupFJHbny8Ic9yKl/0aNHAjHP6VA8/IESc9T7VJhZi5xggdag0IHtlY7hs9cVOFh2jMYB9qI87gAOnTB6UskIjOV++Dmgm5FDIr2v2d2IJPG3qKuwyHB3qnpkjpVLbhDOgHPt0p/wBracxw24wT1zTuDV9jUZ1aID+5TvPtgSHXZkYrLaRlOHBMoqRiWUEKDxzmquTY0g0JXKAYHANNJ81idpxjr61WhkONnOfcVJ5LFflzn+tNMmxXuTtAjxn8KSaWMRAFzn25pz+ZtAA+fvTVi8kbgEPqTQ7lIqqzqSEJ56+9SEnIBGSe1TtG3LIvPpjrVbEvm5fIJ5wKiwxXkI++ExntSIrMrYGY+g9qVYd205GfpxTXjcqCgz6D1pFjC7ReYpx/umi2ii2m4PXPTsKIEdmcyL26k9KEgYnMBBH0oAmCxsfPCEe1AyQ7YKDHbn8qatwzS4IH07UrEFmiJwBzwOv0qgH2zANtjAP86tEYXgfpVOGWCAnBzu6561JcTfugPWmjNob5p82RjyM8Y4qMkTTY4AP4U5JfKIEg4qvKwiffnHPTHNQ2UkEsJXkshJ7elOaeNSggjDkdc96q3bGeWQx5k9+mKrW0phm7OT2IqW+xqoaGjEy3V6Ny49ea1xgjagxWQu2L5T8jduMZ/GnNdGKLGHQnvTTMpq+xqEiIYbkj0qncAkc8xjoAKqLMGbDvjPfFQXF6Q/liYnB4OKdxKDNBr+3VNpJGTzx0qITy3RcQ7MDnn0rPuJkLjGZAOufWoGuApICgZ/SlcrkL0s7TkrOcDrn1qjdbQ2I33j+VI9wGiCPhAO4HNZ8jKJSUJI7ZouUkX4YHmiLIM7OuaqOMEcil3sIAwk4PGM81Cxz9aRpYmjbzITCBFnruPBrLuDtJ9aW4JU1DcoBAHZgST0B6VJSRXLZ5PFKZBjrVdyxH0qsZscZrK5pYsTS8VnTzeXKCKdLPxWVeTfJkdqbBIuSzZ5qvvNR+aWQGmEnPehFHR2twIrgZ6p0NdH50bRSlyfMb7vqK4hnK/Mrde1aNrdyfZyTk91PqaNmS4XN7zDLlUwdg+hqayDLglM4561j2t6swyByBjB9av2BMnDkg9x9Ku5DWh1GmWsskoYg+v41fu2x+7A465FM02Ga3Ek05IiA4BOc1Unu0Aw84yORit4bXOV6srvmKbG4DPO70qdJW86SPiUBc9aqXl9AUCx8nvgYBqvYzsJuWAB4IIrNvqaJNo6yyiWWISIfLIFRXsrQeXhTIc9z0p9tdxxYiIByMhh0NFxdDzcZA45zWqasYq9xtuVKSHL+ppY8KxAOAR1zVLzzENyLsBP1pJZfMEhj+Q54HrUXK5TR83bKGQgjv71I8scnPT+VZUMx4YjHPQVPvwC3UL60KYuQsvKkhygz2zWejzZwrYA6Cp8+dho+uOcU0TlWxIwcYxgDmhu40h27y+xyOo9aaJjkiMYB60jZlbyx1HrwaeG+zkZHXqKRQqy/N+7HJ9eKkGZSCRx04NVvPyT33+3SmKRG/qKVx2L4hDZ884x0GetNt4YWB2Kck8/Sq/n95ADgflT9oLlg2/JyDzVJk2sXGCwjA4HT3pBkyjI4Hf1qHcciPAfPbFDXAJ5zkcfWncmxqqgyC/cVMNuRg47/WsqCfJHOOe9X7ecMSCwOKpMhokaHJJOCe/tUNxEA4wM/QU8TDedrf/XpJg2ORk5qxEc2OnT04qk5PmgYz24qzO2SFBBkPFUtyyv5aHZgnnPNSy0RuzNKBnZ9KmYfMFVRlO9V3mhUAZPmA9+9Lc3aBCY+Oeh61JVmTuFkGwACQ8k5qq8RAHzAnPSoknEUQ2HMp+9kULNwSck9jnoai6LsyV7sYKmNMjpgdKheRjyRyOeO1QbwDkjNDTwnnZgY6Z6UXGkQNdmG6jJ59ferCXrTBzggqSMHuPUVm3nPlknAB9KlEg25B/SoubOndGwkqtiS4m3/7A61BqVzGeIxj8Kzze7RhCQPfrVO7u8jaWHHNHMJUnctwjcn38HrkmlmnZiMnoKrWak5K8gcmld92SFA9hWSZo1qWFkJOc1IrZIzyBVFWIbI5p3mkd6LiaLnmh3OzpmoyQG5PNRQy9cdqT70vtW6IsTe1RzYApzt3HSq88wxkCpFYqTzsuR2qJH3YOag1SYBevJqO1lzECaTZokaBlA61Sed/N46UrNuFNGMUXGtBzS561SvJuuKdKaz7mbqKhsdid5xJbgggY7VQduapxam//HvIe/HFSXBK4qQQksvFUpuUO6l84mXFLccJzRcp6FdJv3IqPzqr/dB570nmUAa9vdPdQwfKnlD071ZgfoM9OcVy3hW9IuhbycxdcV00vyykgYHarS6E3NuymhglkPAjlXI46GtiznMTB9wGR361zVli4iYf8tFOfwrYto1itpJ5AemFH9aSJZ2s2oRzWEapIACeT3xWRMLZoBtPI7gdazhek26fLg46+1LptxLLiNzhM5/GtFPQyULE1zMwiAIIA6cVVe75yRya3xYm75Dpk9fasbUdLe3Oc8e9DV1oa05rZkum6gyXAyxJHY10qANbhpyMnoR61wzt5M8Envg11Fvdm4RBBgSAc9gBWcHZk1YdjVbLRCF2wPcVHcWnff5mzsDjFRQnzsAsfNA7VYtwB/rACe2etbpmGxXUfuuvGKjSZgTv34q7bRJMTxgn0FNe2/0g8ghOOaVhpjIJW8rAJ8s+lLuEMxYMeBwQOaRIQMAZJP4U+dSuSoKA8Z7UINLkP20Fvn5z3NIboMc4qowWKUhwhB/j7VOghWIOpP4DIqWzWyJYW5j3f6v6VNMIW+6HGTxVOGaRQdi9aa4IWRs5Jx0b+lJMViaaEiXakvBPJ71qWsxUfeyc8iseBmLFieaupMTKGJR/TjincU10JZ7iMNsGRLjIz6VB50jcBR1/GnNOVQpgDNUHlMWcZ96tsiCNBZ4yRvbYRx8verlhdKTwcc4IxXLvO2/dnmpra6dX3I2D04qOY0dHQ7qKQFRwMHvinTgn7hI9q5ZL+QRAGTOOcUz+0ZmO7dx6Vp7U5/Ysm1GaRZSp4KHtVOGcwXO4Nv4p1zd5zjjJrPdvc1E3dnRCGhosSzZznNRsfmApkDZ7496GI3gg0rjsSKAWA3Yz1J7VE8uCRnPvTHxjHWq5Y5pNjSL0QVj85PA7VVuGGwYHTqc0JMCMGq05IQ0JlJag7bosVKvyxAVTtzubntVok/hUM0emhDLgtTRFDIxBYJgcHGaa+Pm55FQpjJ5P5VDZSLQOOAaFJziq5HzZp4YVNxWJc8Yo3gDPf6U2IZ5P4UpU4OB061ZIsMvWp0OKpCRRU27itUyZomllqo8vFRyOapTyn15qGwUB13KkxSEQhyecmq9vgLjGPaq7aimn3qTzgn5SAB606CbMIJ6nmovoWlqWt3ajPHNR4wgbI57U5mGKpMlkMxzxWPdD5605jgVlufMl4psaMedjDqMeeVrXuZfMAPpVe5gSRJJCpJUgVaFuRB5nBGKki5kPkNSMxJ5+7Vg4L4xUNxiI/WkirkF2qeb8nSm+VD6/rT7lMImRg4qtTYrmGhOn6hFMnQNkV35vlvbdG3Jg84A6VxF5GJ7YhB+8TkU/w9d/IYSTkdKp33C2p1On3gg1Eeh4roPt8xAgTmP8+K4xlKnzycDtXT6VOZbVJ8exNJPUT0NAy5gRc9Tg1Yhu/JeRY4+ozjtVDazQznHcEVVnZreIAtLknAHQVqkQ2djp2pyeUnaQ87gOa0Asjwfv4DIT0J71x9nOyLFgg9ehro9N1jys5AO4Ckpg4dihNp8ksLswxycZPpVywYsoCKhNWbaV7ua7S3h2OTnHtWSQ0DyIOqHFElfVFp30ZvwXTsh8g7QDgkdatRbTMYA3nS9iewrmLKYiTAP4Gum0yLyHMztzjv3pQZE1YgmmuLckcjPSrO3yYQ3nkyP1A7U3Urv7XFGqRlCjdjnmmDyfuHhyOcnvWjST0M+hbhXdsJdwc49qHlCny1OeeM8ioPNzYkFSMde1VJZwEI+7noBUjSuSPKv3ZF6nue9EGJ3CxkAucEdhVOW5kELwugGSCCeMUaVMy3GVCZx1rJs35NDYmt4Yyw8xPm4wDWdMPIw0bB8dsZ/Op5prbdwMFfTvWZ52HOBwT37VroRBMu7zxxirUMgQg5B9qz7i6mn4PJHAApm8461JVrmjNMYSfMGAfQZqn5qk5K5z6mqzs/dsj3qDedwPWpbGoGu/2aWEB/3cgHbnNZ3STg1oWkMcsTsUXIGMnrWY7L5pHpRuhQ3sWVbjFI0xWokOeahnfBOB0pFWJw5anue1Z8M2TxmpYWyxB5oTKaL8JAGBUkxJxsNUfNwaeZuKu5nYkmJByDio1YdxUE8uR1otjuOOPxrNsq2hMp55z7YqG5BMROfrTXk2nAOKMlk5popBZcIfWpievtVWBsMalJ4oZT+IlS4KQuvGD7ZqrEo2E9yetCEsMcU1Tjis7iQ7JxzSoM5JxgUi8jOKhyQfX6UyjasLsW8DgQxOcZO+qMlwWcnO3d1AqtMQQhB5NLCV35kyY/aqT6GSS3IpfvipWlOKJZVIIBwP51YV7RLfcQ/m46CrZTZnux9Kqu3Hr6VLcybs9aqIQXw/SsWUjG11yZYFHrmtSE/uRnrWZqK+fqsccfOO1aVtFIB846UMaZJ5pzR5nPNQPMDLzwBSblBODmqRmxbyZSOBiqCNtyadO25uKr3jeUvWqGhlgzXF6YST5RbJGa1dTnRVK26kDFZ9nPNBFBM8KGM52nFJqt1+5zwC1LqYozPOYuT2qF3y4yaZ56ldqVTuJvnxQWjc1Ih3iCNn5aynnjRivpUt05ggDMeccVzz3GWJzTSEWbefLdarP/oN8HUHrkU63j8sxl2Bz6Vp62UuLANg+evOcU1q7dxvVGr5sM1nu5JxkVqeGrjzrWW3H8J3jNcVpF2fK2Z6Vt+HL5rXVQMZjb92R9anVK3YT2ud1CZ485ORjeeKzb+RLpyAcEjjnpXQ25jMMg2kfu8bT2rgNcn+yTRGBuc8+1dK2ujJamtbTsccZxxnvWzZKpGcucVyHh67+1+Y0gyQTXX6acAgsUOMDNYPc2T0NrSo5GvisDOkbjg5q9CwimnWCMF3+TcwzVO0xDbPNhMx9Mnrml067j8nAGJRz1q72Rm9SC4hIPTGOtW4JnjCbyTxxz0pGuj028uecilWdSBgfcHPvUdR30NazctCQuPMBGPSoLxz50jXB6DA2jrVO3uGWxkVBy549qZPqUMtjILji46ABetaLYi2pM96YZhGcvnnnvSzzFXGF3n+72FZc032ho2HUdKv2hYD5sAv6dxWVze1iCViT0oQsOcYDDANLeAbgox68UiS7ogSenQHtUvcq+goYqcseKQyFmzkc1E7BhxmoHcgbsYx2qiki7DP+9ycnHpU5uGmCbv5VT0y6UGQmP8AeLk5qMTM0oPOKnpcXJqWpjx8xqtkjntTrkZU+tQOSVp3KSNizmY2Muw81nOwVOuST0q5ojN9mu4e23J4rHmzvJU1a+EhL3mjWsAGBbaTj16VBeSgv6fSrOiTwrZXBePJA61l/bMEgQRuT1LDNStikryYu7HCc4qaIgDOcGqSOd5JULn06VIWwM1Ny2ixvy1TKwNUNxBAIwSM/hT4WODuFFyUi1Jg9KbbMSSF7VXM4BxViD5YSw6njNDHbQiyWl5p80pCYU1DbnLOc9KZO+eKlMm2pElwPO5NWFuBgnNZbQiWX720CrWnBXuY0xkHvRN2Rq0jSkYxHb0yBTV9KNRx9qPQAcVX3980fCZrVF6ZsRMvH1rNc4lznrV2G4KWMpwmDxkislZS8pOM+gob0BIsRTk8ODx0oSc5IpnlmLJmBB+tVrhiAMEc0IErhNOc9c0WkzTZyeKgOMcnmnwAqoDriOQ/ezQ3ct7F9rhbcZC5yOM1m525kc+9T3XzN8vMdVL7Pk7U6mmZbIr2z/6V5469qsPcDnLfvKp2+IYuvX1qO5UIQc5J60rhHYmaQ4yagE2O9Ryy8VXTJNFzSxZ808mqNzum+TPLHHNWHXnlsVQvwy49O5oV2ZTaSNNjNYZsnZHC45BzVW8/fRZqtbEww9MlqS7nxFiq6mNrIoPiLO2q6KZWzU7kPgCrKqIIB/eNMq9kZWrXRYhc8CsnzKn1Jg1wcdKzs1okJFy1lJlKry3YVsfaStsM9fesO7VbW9jMDgg9x61aluTPhtvBoKW9iO2Jhm9s9a6TSp9sySr1zkfUVz/DRcDJFX9NmaPCupRx61L1ImraHt8xzfeYV/1sYlHocivNPFEPmtcbBggkgV6Bori40rS7g5I8kofwriPEJjF7c7F4ycZroX8O5jR3aMPwvceVcSLn/bFdgl0S2e9edaXciC/gk25AOxhmu3MvlsM4H0Nc7VpHRB6WN1JiIfvcfWpbO78m5RsB8Hoe9ZKTMwOAX+laGl2srRCaROO3OKhlaLc1bu4kNweMA8ipLLLS8j92axxMZXjHzkjg1vptjiXI5p7sn4UWblisIhRRjPBx0rKv7Qqkc7yA5OOetbEDRxPuc5iA67c4rP1KTzVkOEw54wOlbdDODdyhbliav205HFVbT7mTUzoV5rA6XqWVOYiz5y/tSqPL8w7M8Yxjip7WS3azxISXTJA9KgMJeAkEDHqaa2uZ31KTofOAwAO2O9TzriE+mKPLGfkO8jrmqtzKTnJHNO5tuTaUvy3E3GNpAOab0I7CrFpbhLGRupkHTHTmoWycUlsO92yzkjHb8Kp3O7qfwq2JmXlDj6VVf96/NJkot6JvW4dAQd6nNUnVvmGO9aGhBTcg/PkcVX2EzPxnBqkvdJv7zLliuzSp8gcnFZhh2nkYrYmzHp0YAA3HNZdycj5yaGvdJpvVsr+agyDECf5Vn3l2qxSD8qnuGGPSq/lKyI7sCC2MGsrnTolcuQFJJpHjyRwOfpUxxn5ar6cSYiXOcknpT3lqiUJNAWlDA4q4pZYGPGO5qrGeMk1LdP8A6KBn75x1pg30IbN8xE4xk0sxApXWO1+VGDgDqDVYy7gamIIhmYA8Vd0dR54mY4VOay1UmU966DR2tIrC7af/AF+MKO1D1dgqO0SncszZY9TzUMl0VhxSXEnBqjNMCcUxwNQTBtKYN94N61QjkK3UZGCF55q3YSL/AGbcKY8ngg+lULPbNO4c7BU9CX1Rq3t810Vyu0gY4rJmOGyas3Eo6A9KpvzyTmrGtAZv73ek3M0u1TmMVXeXBJxlRVi1IA5PNQSXMssW2sS6mLT+WMnHWtVrpIAXkI4HSsZCcy3LdZelPoQ9xCd8oHYdabcTjJIpty3kxZ/jesm4ufepLWpZln5qL+0BFIAKzZrrrzVR5TkEmmlcG+h0kJa5lyDx1NV1Zp5zvJEecAVWTUFi08oh/fuMCtLQbN2twZCSfemtFcwnq7Ft1WKHP5Vz19KWuMDpW1rE4gIjPSsbAnuQIx9avZEFmxtAmGcVDrs3lJxxxV2+m8mEbB0rlNbuiw+Y8mqghN3ZmTTZJqHzRVe4c9B1qPDetb2G2WfN3LkGtTT5DNYS7Dgxnn6VhL8pyOnpWpoMpa4MCkYkUioexo3Zlu2maKTIq5BKWKnPtWWQ0UpU8EGrFtIA+0nG+lbUdTa57t4D/wBI8Jx7MOYpzx7EVyXiG1J1edOnzd6u/C+4ktZvJ8z93IBlazde1OObX7y3jG8oxy2a0pP9212OJXUtDhb8NaalKnTJyK6JWae4t1Ql2K5OKwPE5H25G46V0PgKeA3wE7EeYuzOO9Z1Xpc3hozstJaCytfLkwSRlj/SnHWdxkGB5eOKo6xe2yzSJCRlB2rMW7jazJBGelZfBoaWvqzY03UhDKWCh+e4rYi1COYhY+pPeuMs2zFmtTS5CbqPZ1zWdzT2asdNfXZEqLxyOTTH8t3T7O5eR1ywznBrm9aupIdVljfIOzH6UaQx8o8ntWk9DOCudZY2zTMY3+QpknNR3hbePaqEF2VXvj69anEpkiyTz0qLl2dy+imC2R88v15qZkecbtwf1qrcHbsh3g4FOt7gQFzz04wauGhPmTWgh+7OxDZxio9SMDACNORxu9agnmDchQKqNMSQo7UN2NEru5rpBIlkCQTuGevAqvuK5IOCPSldpvsILnocY9qjRE2EyNjjihbEIBOd/wA5+pqa2Me2UuT0+XFUGnBJCfcFXFJ8sDb2BNLqW0afhuKTzpSFJQEE81VmIN8cjywW/KtPwwdsNwwBxnn6VkBlmvhnJy3rW32WzLeTNbVlhBiSA5HaufuueM9K0tbYrc7QOgxWbcgRQ7iwyamfYdLYz3+9jH51G8eGzHhiik4/SgfM+Sab5xUnY4Ac7CO+B/8AXrBbnRN6WLcOYYgD6UzIYmorm4wKYJcJzVBEsMR0omaNjBDuORk47VXVuM+tT2zKt9cSeXny4cc+tTuTPQrvKc4c9Ki87PAqrLMSSc0lsSTmre5a2uaCuAtXVby7COFxiQneazrSLz7pEPEZOW9hU98WubmWeMcVBDepBdS4HWqXm5OKa8pJOaRBk8UM0Rq2jH7HcBGGMd6iSEwx7ieMcVTEM3necYj5I4BPSrNzMZgN/AFNGV9StPdc1XacmobpgX+SoJJguMjIHWk2aPYumQYAB68mprYliQKxXuxyQOtXbW6EFrIz9SKV+hOyEybzUhb84z8x9BV3VJYOUg4RelR2sJt9PNwf+Pi46ewrJvJzGfL796Zhe7GXLqU+c1z1zP8AOcVJqV0CdoNZ7MD0rRI0vZEiyc80x5ec1AxxyabBuuriOMdzVWM79TW0G1N3fAkZQV6JcLBaWcflnnHNZuj2tvplh58mBxWPqfiJZy8MA6miHcyd2UNTuGu744PTtStdf2fES4w5qwIoLez89x+861yGq37XtyTnjtV2vqI0X1N52OTxWS+64mOOasW0G+IDpmpLkpZR+XHgyGi4zOmg2naOTVyPTzsHFFvCR879TQ94gY8n86e4GUlKh8m4VkOCORTR9aV+xqkdFVXRrX06zeVKAMkc/Wq5ORn0poi/0ZGTJ/vj0p0IJOFo+EhO6seh/DrUZIbmJvMxhTjiuM8T3Df2xcXKcBmJ4Nb/AIVK2/lSZHAbg/SuevJBM8u9QQ36U6TsmYKncp3c/nWwfJODVrTLpovuSYwwPFY0xMIMZFT2T5fFNrQfP7yZ2Am3Kec1aaDyIQGfOf0rHsJPmQuO9az3Kt1HTmuWxvOd3oXbFj5YArodHSEXKGRsAck1ydtdYfnjNbnmr9glYH7orO3vWNX8JXe4+1apcTE5GeM8/St6x2+TnByT0rj9L3M5CEjgZNdrpZH2IMc5Pc1pUd5GMNESZwORVnSZw0z45Veh9Kr6kv8AoQmRfk6A+tP0KJVtZA/Mko79hUWG2PecvKW9TVlpwYcbR9c1jXkyxzHY2fp2ot7kTPjtVN2ZolobsJzCSjpjGTkc1TgJabOR1xz2pizBYiVJwSQKbG/74ZIxnrngVPQSZrXDLIUX05bJ681T1KdS7eQgjT0zUVkBd3QjE3H1qnqzE3EgHAHAqxQ3JLaQb8du+K0HfzXJRsDpgGsPTSfNx1z61ftT+9yTjvWa7ms9zstEi8nSp/MJAbIH+NZuigSasMjgZPStQMsejA5GZDim20CWqS3I+cIuSQOhrqS5opHDz6sq3xgup52dggjPAJ5asvVEXA2Lsz0ptvOpmLnnbziqdzcG4lyT0rOcldm1NNDhJbW9vISpc45qjc24tnh3/wCsEQJHoTzUiRrPcBZDsgTLsT6Cse4vMzEyEvk1OyH9osZzKWkbPtUkZM8uEqiZARx3rV0hVgtJbiTHSszo2RXuZMNtB/Kp0Z4LKefJ+c4znrVSKIzLJcNjHpU7gtawQ/8APRs4p2MpvWxRRS3OMZq1jylyTXQ/2fb20MZcZ45rA1iYNzbgeXnAq7aXYc9yLz2ihdvLx5nAcj+Vbdo0MOkFickVzEk7TSxwE5EfAGeK0bmUwab5BGCTULcTKbnLEipEzg7P9YeAKaHjWLB+/VF51O4ucYOFqdxtmhAWQON5cAYwacynytxqCCeOCEu/3KinvjcD92MJWisLUpzTAOeap+fliM8d6q390olKg1Dp5864wah6al3uy4g82bOOBV60hkuptqfcTqaNwX9zGuXPAq/eD+xdOwWG+QZOKSVzKczP1LU/I4LZI4Wueub/AIJJy5qhf3xnmZs/SqDyHqxrbkBIkmkyck1LbwSyRbgOB3rNWQGUFulbi3PnwiG3U7AOoq2S2VraFrqcIOg610GmWsMGZyoASoNNWFYgANkvc1S13Ucf6Pbt9TRuZtjtY1qbUJfIQ4iBq9ommry8/IA4rB020NxLxWrqt+bS2FvG37yieuiGtClr2olmMCH92OtYsCgnJpWVi2W70+4YDCx1p5CsWp7sQxBY+ZKroCv76c5NV+IvnfrUM9wWqbDLF3eEjAqhv96jJpm6rSGf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cicatricial meibomian gland dysfunction. The meibomian orifices have been dragged into the conjunctiva of the posterior lid margin, which is broadened and highly inflamed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Foulks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4288=[""].join("\n");
var outline_f4_12_4288=null;
var title_f4_12_4289="Osteomalacia of the lumbar spine CT";
var content_f4_12_4289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteomalacia of the lumbar spine: Computerized tomography (CT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 317px; height: 484px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 53-year-old man with osteomalacia. A CT examination revealed ill-defined trabeculae with ground glass appearance consistent with osteomalacia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Farnam, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4289=[""].join("\n");
var outline_f4_12_4289=null;
var title_f4_12_4290="Imaging of Mirizzi syndrome";
var content_f4_12_4290=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mirizzi syndrome seen on magnetic resonance cholangiopancreatography (MRCP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mirizzi syndrome. Two calculi in the dilated cystic duct (arrowheads), which parallels the extrahepatic bile duct. The inferior calculus (arrow) eroded through the wall of the cystic duct into the extrahepatic bile duct, bridging the two structures and resulting in obstruction of the bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eisenberg RL. An atlas of differential diagnosis, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4290=[""].join("\n");
var outline_f4_12_4290=null;
var title_f4_12_4291="Epidermolysis bullosa simplex - hands";
var content_f4_12_4291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epidermolysis bullosa simplex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bullae are present on the hands of this infant with epidermolysis bullosa simplex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4291=[""].join("\n");
var outline_f4_12_4291=null;
var title_f4_12_4292="Role of breast surgery for stage IV breast cancer";
var content_f4_12_4292=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of breast surgery for stage IV breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/12/4292/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/12/4292/contributors\">",
"     Michael S Sabel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/12/4292/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/12/4292/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/12/4292/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/12/4292/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/12/4292/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/12/4292/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with metastatic breast cancer are unlikely to be cured of their disease by any means. Complete remissions from systemic chemotherapy are uncommon, and only a fraction of complete responders remain progression-free for a prolonged period. The median survival for patients with stage IV breast cancer is 18 to 24 months, although the range extends from only a few months to many years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4292/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24278?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging classification for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 3 to 4 percent of women with newly diagnosed breast cancer present with synchronous stage IV disease. A major question that arises in such patients is how best to manage the primary tumor. The role of surgical excision of the primary tumor in stage IV breast cancer is discussed here. Surgical intervention for metastatic disease in these patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35831?source=see_link\">",
"     \"Metastatic breast cancer: Local treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PALLIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of curative treatment for the majority of patients, the goals of therapy typically shift from cure to palliation, focusing on symptom control, improved quality of life (QOL), and prolongation of survival.",
"   </p>",
"   <p>",
"    The typical approach is to perform a core biopsy of the tumor for histologic confirmation of the diagnosis and proceed directly to systemic therapy. Most oncologists consider that once metastases have occurred, there is no survival benefit to aggressive local therapy. However, resection of the primary tumor in stage IV breast disease can provide palliation of bleeding, ulceration or infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4292/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POTENTIAL SURVIVAL BENEFIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a subset of women with metastatic breast cancer who have limited systemic tumor burden and biologically indolent disease. Between 5 and 10 percent of patients with stage IV disease survive five or more years, and 2 to 5 percent become long-term survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4292/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. These long-term survivors tend to be young, with an excellent performance status, and limited metastatic (sometimes referred to as oligometastatic) disease. For such patients, combined modality approaches, often including surgery, appear to provide a better chance for long-term progression-free survival than chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4292/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concept of whether resection of the primary tumor impacts survival has been called into question by several retrospective series that describe better outcomes in patients undergoing breast surgery in the presence of known metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4292/abstract/8-17\">",
"     8-17",
"    </a>",
"    ]. The reason(s) why resection of the primary tumor might improve survival is elusive. Several possibilities exist, including continued dissemination of disease from the primary, increased immune recognition and control of metastatic disease prompted by removal of the primary, or the possibility that the primary tumor may produce factors that promote the growth of distant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4292/abstract/3\">",
"     3",
"    </a>",
"    ] . In addition, some patients with excellent outcomes after surgery in the face of what appears to be metastatic disease may have been incorrectly classified as having stage IV disease.",
"   </p>",
"   <p>",
"    Six of the largest studies of this issue are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef59007 \" href=\"UTD.htm?33/17/34076\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4292/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. A series of 16,023 patients presenting with stage IV breast cancer derived from the National Cancer Data Base; partial or total mastectomy was performed in 9162, while 6861 underwent a variety of diagnostic or palliative procedures but no breast surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4292/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients who had a margin-negative excision had a significantly better three-year survival compared to those who did not (35 versus 26 percent). Perhaps more importantly, women undergoing complete resection of the primary tumor had a significantly better prognosis when compared to those not surgically treated (hazard ratio 0.61, 95% CI, 0.58-0.65), even when the analysis was adjusted for the type and amount of distant disease and the use of systemic therapy.",
"   </p>",
"   <p>",
"    It is likely however, that these retrospective series and others that demonstrate an association between surgery of the primary site and improved survival simply reflect selection bias (ie, patents perceived to have a longer potential survival are more likely to be offered breast surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4292/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. In a review of 19,464 patients with breast cancer, matched pair analysis showed that the survival benefit associated with primary site surgery in stage IV disease was limited to those patients who received chemotherapy initially rather than surgery followed by chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4292/abstract/19\">",
"     19",
"    </a>",
"    ]. This suggests that patients who have an initially good response to initial chemotherapy are selected to proceed to surgery.",
"   </p>",
"   <p>",
"    It is not clear whether the extent of metastatic disease, the sensitivity to chemotherapy of an individual's tumor, or some combination of these factors identify those women who benefit from surgical resection, or simply permit the selection of individuals who would survive longer regardless of primary site surgery. Although the morbidity and mortality of breast surgery is low, the potential benefits of surgery on local control and survival (if any) must be weighed against the negative aspects of surgery, particularly mastectomy, on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"       \"Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=see_link\">",
"       \"Patient information: Treatment of metastatic breast cancer (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with metastatic breast cancer are unlikely to be cured of their disease by any means. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resection of the primary tumor in stage IV breast disease can provide palliation of bleeding, ulceration or infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Palliation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While retrospective studies appear to show a benefit for resection of the primary tumor in women with metastatic breast cancer, this may reflect selection bias and confounding variables. Surgical resection should be considered as a therapeutic option for women with limited metastatic disease, although the risks of surgery must be weighed against the potential benefits. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Potential survival benefit'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/1\">",
"      Lee CG, McCormick B, Mazumdar M, et al. Infiltrating breast carcinoma in patients age 30 years and younger: long term outcome for life, relapse, and second primary tumors. Int J Radiat Oncol Biol Phys 1992; 23:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/2\">",
"      Vogel CL, Azevedo S, Hilsenbeck S, et al. Survival after first recurrence of breast cancer. The Miami experience. Cancer 1992; 70:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/3\">",
"      Leung AM, Vu HN, Nguyen KA, et al. Effects of surgical excision on survival of patients with stage IV breast cancer. J Surg Res 2010; 161:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/4\">",
"      Singletary SE, Walsh G, Vauthey JN, et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 2003; 8:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/5\">",
"      Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/6\">",
"      Falkson G, Gelman RS, Leone L, Falkson CI. Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer 1990; 66:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/7\">",
"      Rivera E, Holmes FA, Buzdar AU, et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J 2002; 8:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/8\">",
"      Carmichael AR, Anderson ED, Chetty U, Dixon JM. Does local surgery have a role in the management of stage IV breast cancer? Eur J Surg Oncol 2003; 29:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/9\">",
"      Nieto Y, Cagnoni PJ, Shpall EJ, et al. Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res 1999; 5:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/10\">",
"      Juan O, Lluch A, de Paz L, et al. Prognostic factors in patients with isolated recurrences of breast cancer (stage IV-NED). Breast Cancer Res Treat 1999; 53:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/11\">",
"      Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002; 132:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/12\">",
"      Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006; 24:2743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/13\">",
"      Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006; 13:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/14\">",
"      Gnerlich J, Jeffe DB, Deshpande AD, et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol 2007; 14:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/15\">",
"      Fields RC, Jeffe DB, Trinkaus K, et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol 2007; 14:3345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/16\">",
"      Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg 2008; 247:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/17\">",
"      Hazard HW, Gorla SR, Scholtens D, et al. Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer 2008; 113:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/18\">",
"      Ruiterkamp J, Ernst MF, van de Poll-Franse LV, et al. Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol 2009; 35:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4292/abstract/19\">",
"      Cady B, Nathan NR, Michaelson JS, et al. Matched pair analyses of stage IV breast cancer with or without resection of primary breast site. Ann Surg Oncol 2008; 15:3384.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 809 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B3512DFB86-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4292=[""].join("\n");
var outline_f4_12_4292=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PALLIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POTENTIAL SURVIVAL BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/809\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/809|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/17/34076\" title=\"table 1\">",
"      Prim resect met br ca",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35831?source=related_link\">",
"      Metastatic breast cancer: Local treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=related_link\">",
"      Patient information: Treatment of metastatic breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24278?source=related_link\">",
"      Tumor node metastasis (TNM) staging classification for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_12_4293="Hand-foot-and-mouth disease - lip and hand";
var content_f4_12_4293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-foot-and-mouth disease - lip and hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Oral lesion: note the oval shape and rim of erythema. B) Oval intact vesicles are noted on the palm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4293=[""].join("\n");
var outline_f4_12_4293=null;
var title_f4_12_4294="Pneumococcal polysaccharide vaccine (23-valent): Pediatric drug information";
var content_f4_12_4294=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pneumococcal polysaccharide vaccine (23-valent): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"    see \"Pneumococcal polysaccharide vaccine (23-valent): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/5/14417?source=see_link\">",
"    see \"Pneumococcal polysaccharide vaccine (23-valent): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pneumovax&reg; 23",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pneumo 23&trade;;",
"     </li>",
"     <li>",
"      Pneumovax&reg; 23",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"      see \"Pneumococcal polysaccharide vaccine (23-valent): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;2 years, Adolescents, and Adults: I.M.; SubQ: 0.5 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Primary vaccination: Children with specified underlying medical conditions: One dose of PPSV23 should be given at &ge;2 years of age. Immunization with PCV13 should be completed prior to PPSV23 as recommended. The minimum interval between the last dose of PCV13 and PPSV23 is 8 weeks (AAP, 2010; CDC 59[11], 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Revaccination: Children with functional or anatomic asplenia or who are immunocompromised: One revaccination dose &ge;5 years after the first dose of PPSV23. Revaccination of immunocompetent individuals is generally not recommended (CDC 59[11], 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: I.M., SubQ: 0.5 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Primary vaccination: Adults 19-64 years of age with specified underlying medical conditions and all patients at 65 years of age without previous PPSV23 vaccination should receive one dose of PPSV23 (CDC, 59[34], 2010). In patients who are pneumococcal vaccine-na&iuml;ve (no previous PCV13 or PPSV23 vaccine), administer a single dose of PCV13 followed by 1 dose of PPSV23 8 weeks later (CDC, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Revaccination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults 19-64 years of age with functional or anatomic asplenia or who are immunocompromised: One revaccination dose &ge;5 years after first dose of PPSV23 (CDC, 59[34], 2010) and &ge;8 weeks after PCV13 (CDC, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults &ge;65 years: One revaccination dose if &ge;5 years after first dose of PPSV23 and if &lt;65 years of age at the time of the initial vaccination (for any indication). Immunocompetent adults who received primary vaccination at &ge;65 years do not need to be revaccinated (CDC, 59[34], 2010; CDC, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F210854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pneumovax&reg; 23: 25 mcg each of 23 capsular polysaccharide isolates/0.5 mL (0.5 mL, 2.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F210842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer SubQ or I.M. either the anterolateral aspect of the thigh or arm;",
"     <b>",
"      not for I.V. or intradermal administration",
"     </b>",
"     . Adolescents and adults should be vaccinated while seated or lying down. U.S. law requires that the date of administration; the vaccine manufacturer; lot number of vaccine; and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     To provide immunization against pneumococcal disease caused by serotypes included in the vaccine (FDA approved in children &ge;2 years of age and adults).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for patients with the following underlying medical conditions (CDC, 59[11], 2010; CDC, 59[34], 2010; CDC, 2012):",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Immunocompromised children &ge;2 years and adults 19-64 years",
"     </b>",
"     with congenital or acquired  immunodeficiency (includes B or T cell deficiency, compliment deficiencies and phagocytic disorders; excludes chronic granulomatous disease), HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancies, solid organ transplant, multiple myeloma, or other diseases requiring immunosuppressive drugs (including long-term systemic corticosteroids and radiation therapy)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Children &ge;2 years and adults 19-64 years",
"     </b>",
"     with functional or anatomic asplenia, including sickle cell disease or other hemoglobinopathies, congenital or acquired asplenia, splenic dysfunction, or splenectomy",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Immunocompetent children &ge;2 years",
"     </b>",
"     with chronic heart disease (particularly cyanotic congenital heart disease and heart failure), chronic lung disease (including asthma if treated with high dose corticosteroids), diabetes, cerebrospinal fluid leaks, or cochlear implants",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Immunocompetent adults 19-64 years",
"     </b>",
"     with chronic heart disease (including heart failure and cardiomyopathies; excluding hypertension), chronic lung disease (including COPD, emphysema, and asthma), diabetes, cerebrospinal fluid leaks, cochlear implants, alcoholism, chronic liver disease, cirrhosis, and cigarette smokers",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      All adults &ge;65 years",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pneumococcal 23-Valent Polysaccharide Vaccine (Pneumovax&reg; 23) may be confused with Pneumococcal 7-Valent Conjugate Vaccine (Prevnar&reg;) or with Pneumococcal 13-Valent Conjugate Vaccine (Prevnar 13&reg;)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F210882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Central nervous system: Chills, Guillain-Barr&eacute; syndrome, fever &le;102&deg;F*, fever &gt;102&deg;F, headache, malaise, pain, radiculoneuropathy, seizure (febrile)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Angioneurotic edema, cellulitis, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Hemolytic anemia (in patients with other hematologic disorders), leukocytosis, thrombocytopenia (in patients with stabilized ITP)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Injection site reaction* (erythema, induration, swelling, soreness, warmth); peripheral edema in injected extremity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis, limb mobility decreased, myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylactoid reaction, C-reactive protein increased, lymphadenitis, lymphadenopathy, serum sickness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     *Reactions most commonly reported in clinical trials.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pneumococcal vaccine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy, including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use caution in patients with severe cardiovascular or pulmonary disease where a systemic reaction may pose a significant risk. Patients who will be receiving immunosuppressive therapy (including Hodgkin's disease, cancer chemotherapy, or transplantation) should be vaccinated at least 2 weeks prior to the initiation of immunosuppressive therapy. Immune responses may be impaired for several months following intensive immunosuppressive therapy (up to 2 years in Hodgkin's disease patients). Patients who will undergo splenectomy or cochlear implant should also be vaccinated at least 2 weeks prior to surgery, if possible. Patients with HIV should be vaccinated as soon as possible (following confirmation of the diagnosis). Not recommended in children &lt;2 years of age. Use caution in patients with severe cardiovascular or pulmonary disease where a systemic reaction may pose a significant risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Administer with caution to patients with thrombocytopenia or any coagulation disorder that would be compromised by I.M. injection; if the patient receives antihemophilia or other similar therapy, I.M. injection can be scheduled shortly after such therapy is administered. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for anaphylactoid or acute hypersensitivity reactions should be available during vaccine use; intradermal administration may cause severe local reactions. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F210849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zoster Vaccine: Pneumococcal Polysaccharide Vaccine (Polyvalent) may diminish the therapeutic effect of Zoster Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F210851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F210862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Vaccination should be considered in pregnant women at high risk for infection. Inactivated vaccines have not been shown to cause increased risks to the fetus (CDC, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13929222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although there are more than 80 known pneumococcal capsular types, pneumococcal disease is mainly caused by only a few types of pneumococci. Pneumococcal vaccine contains capsular polysaccharides of 23 pneumococcal types which represent at least 98% of pneumococcal disease isolates in the United States and Europe. The pneumococcal vaccine with 23 pneumococcal capsular polysaccharide types became available in 1983. The 23 capsular pneumococcal vaccine contains purified capsular polysaccharides of pneumococcal types 1, 2, 3, 4, 5, 8, 9, 12, 14, 17, 19, 20, 22, 23, 26, 34, 43, 51, 56, 57, 67, 70 (American Classification). These are the main pneumococcal types associated with serious infections in the United States.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/5/14417?source=see_link\">",
"      see \"Pneumococcal polysaccharide vaccine (23-valent): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This vaccine is used to prevent pneumococcal disease which causes bacterial meningitis and pneumonia. Side effects from this vaccine include redness, tenderness, or swelling at the injection site and mild fever. Contact your healthcare provider immediately for high fever or signs of allergic reaction (respiratory difficulty, hoarseness or wheezing, hives, paleness, weakness, fast heartbeat, dizziness, swelling of the throat).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10284975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4294/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Advisory Committee on Immunization Practices, &ldquo;Preventing Pneumococcal Disease Among Infants and Young Children. Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2000, 49(RR-9):1-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4294/abstract-text/11055835/pubmed\" id=\"11055835\" target=\"_blank\">",
"        11055835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, \"Recommendations for the Prevention of",
"      <i>",
"       Streptococcus pneumoniae",
"      </i>",
"      Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(1):186-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4294/abstract-text/20498180/pubmed\" id=\"20498180\" target=\"_blank\">",
"        20498180",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention of Pneumococcal Disease Among Infants and Children - Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-11):1-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4294/abstract-text/21150868/pubmed\" id=\"21150868\" target=\"_blank\">",
"        21150868",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4294/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23),\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2010, 59(34):1102-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4294/abstract-text/20814406/pubmed\" id=\"20814406\" target=\"_blank\">",
"        20814406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61:816-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4294/abstract-text/23051612/pubmed\" id=\"23051612\" target=\"_blank\">",
"        23051612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davidson M, Bulkow LR, Grabman J, et al, &ldquo;Immunogenicity of Pneumococcal Revaccination in Patients With Chronic Disease,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1994, 154(19):2209-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4294/abstract-text/7944842/pubmed\" id=\"7944842\" target=\"_blank\">",
"        7944842",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardner P and Schaffner W, &ldquo;Immunization of Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(17):1252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4294/abstract-text/8464436/pubmed\" id=\"8464436\" target=\"_blank\">",
"        8464436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4294/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Pneumococcal Vaccination for Cochlear Implant Recipients,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2002, 51(41):931.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4294/abstract-text/12408148/pubmed\" id=\"12408148\" target=\"_blank\">",
"        12408148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1997, 46(RR-8):1-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4294/abstract-text/9132580/pubmed\" id=\"9132580\" target=\"_blank\">",
"        9132580",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4294/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12948 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4294=[""].join("\n");
var outline_f4_12_4294=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210866\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210867\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061157\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061150\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210854\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210842\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061161\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061153\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061160\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914139\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210882\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061163\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061149\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061148\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299892\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210849\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210851\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210862\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13929222\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061147\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061155\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10284975\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12948\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12948|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=related_link\">",
"      Pneumococcal polysaccharide vaccine (23-valent): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/5/14417?source=related_link\">",
"      Pneumococcal polysaccharide vaccine (23-valent): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_12_4295="Reactions to the hemodialysis membrane";
var content_f4_12_4295=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reactions to the hemodialysis membrane",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/12/4295/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/12/4295/contributors\">",
"     Alessandro Bellucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/12/4295/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/12/4295/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/12/4295/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/12/4295/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/12/4295/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialyzer reactions refer to all of the abnormal sequelae resulting from the interaction between blood constituents and the hemodialysis membrane. There are two types of reactions: type A and type B [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/1\">",
"     1",
"    </a>",
"    ]. In the past, these reactions were grouped under the term \"first use syndrome\" because they primarily occurred with new dialyzers. Before discussing the characteristics of these disorders, it is helpful to review the different types of dialyzers, since they can affect the frequency and type of reaction seen. The longer term clinical consequences of exposure to dialysis membranes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=see_link\">",
"     \"Clinical consequences of hemodialysis membrane biocompatibility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF HEMODIALYSIS MEMBRANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four types of membranes currently used to manufacture dialyzers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cellulose, also called cuprophan (or cuprophane), is a polysaccharide-based membrane obtained from pressed cotton. It is composed of chains of glucosan rings with abundant free hydroxyl groups.",
"     </li>",
"     <li>",
"      Substituted cellulose membranes are obtained by chemical bonding of a material to the free hydroxyl groups at the surface of the cellulose polymer. The most common type is cellulose acetate, in which acetate replaces 80 percent of the hydroxyl groups.",
"     </li>",
"     <li>",
"      Cellulosynthetic membranes are modified by the addition of a synthetic material (such as diethylaminoethyl in the production of Hemophane&reg;) to liquefied cellulose during its formation.",
"     </li>",
"     <li>",
"      Synthetic noncellulose membranes which have a higher permeability and are more biocompatible (and more expensive) than the cellulose membranes. There are a variety of synthetic membranes available, including polyacrylonitrile (PAN), acrylonitrile-sodium methallyl sulfonate (AN-69), polysulfone, polycarbonate, polyamide, and polymethylmethacrylate (PMMA) membranes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPE A REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type A reactions are estimated to occur in approximately four of every 100,000 dialysis treatments. They usually begin in the",
"    <strong>",
"     first few minutes",
"    </strong>",
"    of dialysis, immediately after the return of blood from the dialysis circuit to the patient; in occasional cases, however, the onset is delayed for up to 30 minutes into the treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The associated symptoms range from mild to severe [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/1\">",
"     1",
"    </a>",
"    ]. Mild cases may be associated with a variety of symptoms such as itching, burning sensation at the access site, urticaria, flushing, cough, sneezing, wheezing, abdominal cramps, diarrhea, headache, back and chest pain, nausea, vomiting, fever, and chills. More severe reactions lead to dyspnea, a sense of impending doom, and hypotension, potentially resulting in cardiac arrest and death. Patients with an allergic diathesis and eosinophilia appear to be predisposed to this type of reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type A reactions are probably largely caused by leachable substances from the dialyzer or by contamination with bacterial peptides. A classic cause of this type of reaction is",
"    <strong>",
"     ethylene oxide",
"    </strong>",
"    , which is used to sterilize hollow fiber dialyzers. Reactions to ethylene oxide, which are now uncommon, occur exclusively during the first use, usually when there has been inadequate rinsing of the dialyzer prior to use. IgE antibodies directed against ethylene oxide are present in some cases, particularly those with more severe reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study, for example, found that 16 of 106 unselected patients developed mild allergic symptoms after hemodialysis; ten of these patients also developed eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/4\">",
"     4",
"    </a>",
"    ]. Two observations suggested an important role for ethylene oxide in this response: allergy to ethylene oxide could be demonstrated in seven of the cases; and the symptoms and eosinophilia were ameliorated in three patients by ethylene oxide-free hemodialysis. Patients with eosinophilia also have a greater degree of complement activation and interleukin-2 production after exposure to a cuprophane membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. These exaggerated responses may be related in part to an underlying allergic diathesis.",
"   </p>",
"   <p>",
"    A high incidence of anaphylactoid reactions is also seen when angiotensin converting enzyme (ACE) inhibitors are used in patients treated with high-flux hemodialysis using AN-69 dialyzers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. One report, for example, surveyed dialysis centers reporting anaphylactic reactions (AR) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/6\">",
"     6",
"    </a>",
"    ]. An AR developed in 41 of 72 patients (57 percent) treated with an ACE inhibitor and dialyzed with an AN-69 membrane. In contrast, an AR developed in none of the 71 patients taking an ACE inhibitor but dialyzed with other membranes and in only 2 of 519 patients (0.4 percent) dialyzed with AN-69 membrane but not treated with an ACE inhibitor.",
"   </p>",
"   <p>",
"    These membranes appear to act by increasing the rate of kinin generation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The following mechanism has been proposed to explain the susceptibility associated with AN-69 membranes. Contact of blood with a dialysis membrane leads to binding of Hageman factor (factor XII) and circulating complexes of high molecular weight kininogen with prekallikrein. Activation of prekallikrein by Hageman factor results in the formation of kallikrein, which cleaves bradykinin from kininogen. Activation of this process is facilitated by a negatively charged surface which induces conformational changes in Hageman factor. Polyacrylonitrile membranes are highly negatively charged, while cellulosic membranes have a neutral charge [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ensuing enhancement of bradykinin production is generally well tolerated unless the patient is taking an angiotensin converting enzyme (ACE) inhibitor. Angiotensin converting enzyme is also a kininase. Thus, blocking converting enzyme prevents inactivation of bradykinin, thereby raising bradykinin levels as much as",
"    <strong>",
"     20 to 30 fold",
"    </strong>",
"    and increasing the likelihood of an anaphylactoid reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association of AR with hypochlorite (bleach) reprocessed but not formalin reprocessed AN-69 dialyzers is also consistent with the importance of surface activation of Hageman factor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/11\">",
"     11",
"    </a>",
"    ]. Hypochlorite, a strong oxidizing agent, removes the protein coat from the used dialysis membranes and is therefore likely to activate factor XII. On the other hand, formaldehyde fixes the protein layer on the surface, thereby reducing the chance for further activation of the Hageman factor.",
"   </p>",
"   <p>",
"    The use of AN-69 membranes for continuous renal replacement therapy (CRRT) has moved the occurrence of this type of reaction from the dialysis unit to the critical care setting. Priming of the CRRT circuit with packed red blood cells has been associated with severe hypotension, which was only responsive to the removal of the CRRT circuit in two pediatric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/12\">",
"     12",
"    </a>",
"    ]. Neither of these children was on an ACE inhibitor. The reaction was prevented by buffering the blood to a physiologic pH prior to priming the CRRT circuit or by infusing the packed red blood cells after the dialyzer (post-dilution). The authors postulated that an acid pH enhanced the generation of bradykinins at the time of the blood-membrane interaction. This raises the possibility that alkali administration may prevent anaphylactoid reactions in patients on ACE-inhibitors dialyzed with the AN-69 membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surface treatment of AN-69 membrane with a biocompatible polymer (AN-69 ST) results in partial neutralization of the surface electronegativity dramatically reducing bradykinin release [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients with history of anaphylactoid reaction to AN-69 membranes while taking ACE-inhibitors have been successfully dialyzed with AN-69 ST membranes while still taking the ACE-inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/15\">",
"     15",
"    </a>",
"    ]. This experience further confirms the role of the electronegative charge and the generation of bradykinins as the causative factor for these reactions.",
"   </p>",
"   <p>",
"    Anaphylactoid reactions have also been associated with reused polysulfone and cellulose acetate dialyzers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/16\">",
"     16",
"    </a>",
"    ]. However, the role of ACE inhibitors in this setting is less certain.",
"   </p>",
"   <p>",
"    Anaphylactoid reactions have also been reported among patients receiving angiotensin II receptor blockers during hemodialysis with AN69 membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, since ARBs do not affect bradykinin levels, the exact underlying mechanism is unclear.",
"   </p>",
"   <p>",
"    Type A reactions can also be seen in a number of other settings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High flux dialyzers used in conjunction with bicarbonate dialysate are susceptible to contamination with bacterial peptides.",
"     </li>",
"     <li>",
"      Rarely, type A reactions are seen with reused dialyzers. No association was found with the disinfectant, the reprocessing method (manual or automated) or type of dialysate (bicarbonate or acetate). Multivariate analysis showed an increased risk with the practice of washing the hemodialyzer blood compartment with either bleach or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      and acetate can precipitate type A reactions, potentially causing severe bronchospasm.",
"     </li>",
"     <li>",
"      Formaldehyde [",
"      <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/20\">",
"       20",
"      </a>",
"      ] and natural rubber latex [",
"      <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/21\">",
"       21",
"      </a>",
"      ] have also been linked to anaphylactoid reactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dialysis treatment is immediately stopped",
"    <strong>",
"     without returning the blood to the patient",
"    </strong>",
"    . The patient is then treated, depending upon the severity of the symptoms, with antihistamines, steroids, epinephrine, bronchodilators,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pressors.",
"   </p>",
"   <p>",
"    Type A reactions can usually be prevented by proper rinsing of the dialyzer, adequate sterilization techniques for the dialysis machine, reuse of the dialyzer, and avoiding PAN membranes in patients treated with an ACE inhibitor. Sterilization of the dialyzer with gamma irradiation or steam and pretreatment with antihistamines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    steroids may be necessary during the first use in patients with a previous history of a type A reaction.",
"   </p>",
"   <p>",
"    Reuse of the dialyzer with proper sterilization techniques prevents most reactions, probably because the dialyzer membrane is coated with proteins from the patient plasma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7096?source=see_link\">",
"     \"Reuse of dialyzers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TYPE B REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type B reactions are more common and fortunately less severe than type A reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/1\">",
"     1",
"    </a>",
"    ]. They occur in 3 to 5 percent of patients dialyzed with new cellulosic membranes. The most common symptoms are chest and back pain, dyspnea, nausea, vomiting, and hypotension. Anaphylaxis is extremely rare.",
"   </p>",
"   <p>",
"    In addition to the difference in symptoms there are two other important characteristics that distinguish these reactions from type A reactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms are delayed, as opposed to the usual occurrence within the first few minutes with type A reactions. Type B reactions typically begin within the",
"      <strong>",
"       first 15 to 30 minutes",
"      </strong>",
"      of the dialysis treatment, but occasionally much later.",
"     </li>",
"     <li>",
"      There is generally an",
"      <strong>",
"       improvement",
"      </strong>",
"      in symptoms with continuation of the dialysis treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type B reactions are believed to be mediated by",
"    <strong>",
"     complement",
"    </strong>",
"    . The free hydroxyl groups on the dialysis membrane activate the alternate pathway of complement, leading to neutrophil activation and subsequent sequestration in the pulmonary circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9911?source=see_link\">",
"     \"Biochemical mechanisms involved in blood-hemodialysis membrane interactions\"",
"    </a>",
"    .) These changes are frequently associated with marked and transient neutropenia, beginning as early as one minute after the start of dialysis with the nadir in the white cell count being reached within 15 minutes. This is followed by an increased number of immature neutrophils (bands) appearing in the circulation, returning the neutrophil count to predialysis values by one hour. At this time, however, the band count may reach levels three times normal, an effect that may persist for as long as five hours (",
"    <a class=\"graphic graphic_figure graphicRef51319 \" href=\"UTD.htm?37/24/38285\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The lymphocyte count is also affected during this response. It tends to remain stable for the first 30 minutes of dialysis and then increases during the next 30 minutes to levels averaging twice the baseline value.",
"   </p>",
"   <p>",
"    Animal studies have shown that the neutropenia is almost entirely explained by the sequestration of neutrophils in the pulmonary capillary bed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/22\">",
"     22",
"    </a>",
"    ]. Furthermore, the timing of activation of the complement parallels the changes in leukocyte count. C3a formation begins immediately after blood is exposed to a new cuprophane dialyzer; maximal plasma C3a levels are seen at 15 minutes and return to normal values within 10 minutes of completing dialysis (",
"    <a class=\"graphic graphic_figure graphicRef61355 \" href=\"UTD.htm?15/25/15774\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients who exhibit the first-use syndrome consistently activate complement and raise the serum levels of C3a to a greater degree than patients who do not have this reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although C3a levels most accurately reflect the extent of complement activation, it is C5a that is responsible for promoting leukocyte sequestration in the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/25\">",
"     25",
"    </a>",
"    ]. C5a binds to plasma membrane receptors on neutrophils, leading to activation, aggregation, and adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/26\">",
"     26",
"    </a>",
"    ]. This is followed by downregulation of the receptor sites with resultant cellular unresponsiveness and release of deactivated granulocytes from the pulmonary capillaries back into the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complement activation is importantly determined by the type of membrane used, being progressively less as the biocompatibility of the membrane increases (",
"    <a class=\"graphic graphic_figure graphicRef61355 \" href=\"UTD.htm?15/25/15774\">",
"     figure 2",
"    </a>",
"    ). The types of dialysis membranes listed above can be listed in decreasing order of biocompatibility:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Synthetic membranes (most biocompatible)",
"     </li>",
"     <li>",
"      Reused cellulose",
"     </li>",
"     <li>",
"      Cellulosynthetic (Hemophan)",
"     </li>",
"     <li>",
"      Substituted cellulose (cellulose acetate)",
"     </li>",
"     <li>",
"      Cellulose (cuprophane) (least biocompatible)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cellulose acetate dialyzers appear to possess only about one-half the complement activating property of new cuprophane dialyzers, while polyacrylonitrile membranes induce minimal complement activation and do not lead to leukopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/25\">",
"     25",
"    </a>",
"    ]. Synthetic polysulfone membranes are able to activate the complement pathway but the complement products are then absorbed, thereby blunting their effect. The degree of complement activation is also proportional to dialyzer size, but not to the blood flow rate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the transient release of C3a and C5a, ongoing generation of the terminal complement components (C5b-9) continues throughout the dialysis session and possibly for several hours afterward [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/29\">",
"     29",
"    </a>",
"    ]. The terminal complement components are able to activate mononuclear cells to release various cytokines, such as tumor necrosis factor and interleukin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/30\">",
"     30",
"    </a>",
"    ]. This may contribute to other complications associated with hemodialysis such as enhanced tissue catabolism, a greater risk of infection, increased beta-2 microglobulin generation, and perhaps more rapid loss of residual renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=see_link\">",
"     \"Clinical consequences of hemodialysis membrane biocompatibility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of type B reactions is typically supportive, since the symptoms characteristically resolve as dialysis is continued. The syndrome can be minimized or prevented by",
"    <strong>",
"     reuse",
"    </strong>",
"    of the dialyzer which reduces complement activation and leukopenia by 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7096?source=see_link\">",
"     \"Reuse of dialyzers\"",
"    </a>",
"    .) This protective effect is thought to result from coating of the free hydroxyl groups by plasma proteins. In some cases, it may be necessary to change to a more biocompatible membrane to relieve symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OTHER REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seven dialysis patients at one center developed unusual clinical features after exposure to old cellulose acetate membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/31\">",
"     31",
"    </a>",
"    ]. These manifestations, which appeared 7 to 24 hours after a dialysis treatment, variably included decreased vision and hearing, conjunctivitis, headache, confusion, corneal opacification, and cardiac arrest. An investigation by the Centers for Disease Control and Prevention and the Food and Drug Administration (both of the United States) concluded that the outbreak was due to exposure to cellulose acetate degradation products resulting from the use of very old (11.5 years) cellulose acetate dialyzer membranes. Thus, the stock of dialysis membranes should be properly rotated and the manufacturers should clear the use of membranes suspected of being old. The date of manufacture is now required to be placed on all new dialyzers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H19#H19\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Red eye syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute complications are common during hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link\">",
"     \"Acute complications during hemodialysis\"",
"    </a>",
"    .) Most of these intradialytic events are relatively easy to recognize and treat and potentially fatal reactions rarely occur.",
"   </p>",
"   <p>",
"    The following are specific events and their general time of onset of symptoms with respect to the initiation of the dialysis session. This is an important clue to properly diagnose and treat these events [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4295/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type A dialyzer reactions most frequently occur within the first 10 minutes; they occur less often later but still during the first hour.",
"     </li>",
"     <li>",
"      The onset of type B dialyzer reactions are after 30 minutes and up to the first hour; it is uncommon after this period.",
"     </li>",
"     <li>",
"      Although it can happen at any time, hemolysis most often occurs during the first hour. Multiple patients may be simultaneously involved.",
"     </li>",
"     <li>",
"      Air embolism most frequently occurs at dialysis initiation in patients with central venous catheters. It is uncommon otherwise, but can happen at any time.",
"     </li>",
"     <li>",
"      Dialysis-associated episodic hypotension is rare at initiation unless pericardial tamponade or valvular heart disease is present. It is more common in the later stages of treatment.",
"     </li>",
"     <li>",
"      Dialysis-induced hypoxemia peaks at 30 minutes and improves after the second hour.",
"     </li>",
"     <li>",
"      Dialysis dysequilibrium most frequently occurs toward the end of the treatment or immediately thereafter. It may happen sooner if dialysate is hypotonic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1453243052\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dialyzer reactions refer to all of the abnormal sequelae resulting from the interaction between blood constituents and the hemodialysis membrane. There are two types of reactions: type A and type B. Type A is far less common but more severe than type B. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Type A reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Type A reactions usually begin in the first few minutes of dialysis although the onset may be delayed for up to 30 minutes. Mild symptoms include itching, burning sensation at the access site, urticaria, flushing, cough, sneezing, wheezing, abdominal cramps, diarrhea, headache, back and chest pain, nausea, vomiting, fever, and chills. More severe reactions lead to dyspnea, a sense of impending doom, and hypotension, potentially resulting in cardiac arrest and death. Type A reactions are probably caused by leachable substances from the dialyzer (such as ethylene oxide) or by contamination with bacterial peptides. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Type A reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high incidence of anaphylactoid reactions is seen when angiotensin converting enzyme (ACE) inhibitors are used in patients treated with high-flux hemodialysis using AN-69 dialyzers. These membranes increase bradykinin levels. Since angiotensin converting enzyme is also a kininase, blocking the enzyme prevents inactivation of bradykinin which increases the likelihood of an anaphylactoid reaction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of a type A reaction is stopping dialysis immediately without returning the blood to the patient. Other therapies that may be used include antihistamines, steroids, epinephrine, bronchodilators,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pressors, depending upon the severity of symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment and prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type A reactions can usually be prevented by proper rinsing of the dialyzer, adequate sterilization techniques for the dialysis machine, reuse of the dialyzer, and avoiding PAN membranes in patients treated with an ACE inhibitor. Sterilization of the dialyzer with gamma irradiation or steam and pretreatment with antihistamines",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      steroids may be necessary during the first use in patients with a previous history of a type A reaction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment and prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type B reactions occur in 3 to 5 percent of patients dialyzed with new cellulosic membranes and are mediated by complement. The most common symptoms are chest and back pain, dyspnea, nausea, vomiting, and hypotension. Anaphylaxis is extremely rare. In contrast to type A reactions, type B symptoms typically do not occur until 15 to 30 minutes into the dialysis treatment, and there is generally an improvement in symptoms with continuation of the dialysis treatment. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Type B reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of type B reactions is typically supportive, since the symptoms characteristically resolve as dialysis is continued. The syndrome can be minimized or prevented by reuse of the dialyzer. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment and prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis of type and B reactions include other acute complications of dialysis such as hemolysis, air embolism, dialysis-associated episodic hypotension, dialysis-induced hypoxemia and dialysis dysequilibrium. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/1\">",
"      Daugirdas JT, Ing TS. First-use reactions during hemodialysis: a definition of subtypes. Kidney Int Suppl 1988; 24:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/2\">",
"      Bour&eacute; T, Vanholder R. Which dialyser membrane to choose? Nephrol Dial Transplant 2004; 19:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/3\">",
"      Lemke HD, Heidland A, Schaefer RM. Hypersensitivity reactions during haemodialysis: role of complement fragments and ethylene oxide antibodies. Nephrol Dial Transplant 1990; 5:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/4\">",
"      R&ouml;ckel A, Klinke B, Hertel J, et al. Allergy to dialysis materials. Nephrol Dial Transplant 1989; 4:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/5\">",
"      Hertel J, Kimmel PL, Phillips TM, Bosch JP. Eosinophilia and cellular cytokine responsiveness in hemodialysis patients. J Am Soc Nephrol 1992; 3:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/6\">",
"      Parnes EL, Shapiro WB. Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney Int 1991; 40:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/7\">",
"      Brunet P, Jaber K, Berland Y, Baz M. Anaphylactoid reactions during hemodialysis and hemofiltration: role of associating AN69 membrane and angiotensin I-converting enzyme inhibitors. Am J Kidney Dis 1992; 19:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/8\">",
"      Simon P, Potier J, Thebaud HE. [Risk factors for acute hypersensitivity reactions in hemodialysis]. Nephrologie 1996; 17:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/9\">",
"      Schulman G, Hakim R, Arias R, et al. Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction. J Am Soc Nephrol 1993; 3:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/10\">",
"      Verresen L, Fink E, Lemke HD, Vanrenterghem Y. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int 1994; 45:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/11\">",
"      Kuwahara T, Markert M, Wauters JP. Biocompatibility aspects of dialyzer reprocessing: a comparison of 3 re-use methods and 3 membranes. Clin Nephrol 1989; 32:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/12\">",
"      Brophy PD, Mottes TA, Kudelka TL, et al. AN-69 membrane reactions are pH-dependent and preventable. Am J Kidney Dis 2001; 38:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/13\">",
"      Lacour F, Maheut H. [AN 69 membrane and conversion enzyme inhibitors: prevention of anaphylactic shock by alkaline rinsing?]. Nephrologie 1992; 13:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/14\">",
"      Thomas M, Valette P, Mausset AL, D&eacute;jardin P. High molecular weight kininogen adsorption on hemodialysis membranes: influence of pH and relationship with contact phase activation of blood plasma. influence of pre-treatment with poly(ethyleneimine). Int J Artif Organs 2000; 23:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/15\">",
"      Maheut H, Lacour F. Using AN69 ST membrane: a dialysis centre experience. Nephrol Dial Transplant 2001; 16:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/16\">",
"      Pegues DA, Beck-Sague CM, Woollen SW, et al. Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Int 1992; 42:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/17\">",
"      Bijin, J. Anaphylactic reaction during haemodialysis on AN69 membrane in a patient receiving angiotensin II receptor antagonist. Nephrol Dial Transplant 2001; 16:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/18\">",
"      Krieter DH, Canaud B. Anaphylactic reaction during haemodialysis on AN69 membrane in a patient receiving angiotensin II receptor antagonist. Nephrol Dial Transplant 2002; 17:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/19\">",
"      Acute allergic reactions associated with reprocessed hemodialyzers&mdash;United States, 1989-1990. MMMR 1991; 40(9); 147:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/20\">",
"      Maurice F, Rivory JP, Larsson PH, et al. Anaphylactic shock caused by formaldehyde in a patient undergoing long-term hemodialysis. J Allergy Clin Immunol 1986; 77:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/21\">",
"      Spart&agrave; G, Kemper MJ, Gerber AC, et al. Latex allergy in children with urological malformation and chronic renal failure. J Urol 2004; 171:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/22\">",
"      Craddock PR, Fehr J, Dalmasso AP, et al. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977; 59:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/23\">",
"      Hakim RM, Breillatt J, Lazarus JM, Port FK. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 1984; 311:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/24\">",
"      Chenoweth DE. Complement activation during hemodialysis: clinical observations, proposed mechanisms, and theoretical implications. Artif Organs 1984; 8:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/25\">",
"      Chenoweth DE, Cheung AK, Henderson LW. Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes. Kidney Int 1983; 24:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/26\">",
"      Tabor B, Geissler B, Odell R, et al. Dialysis neutropenia: the role of the cytoskeleton. Kidney Int 1998; 53:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/27\">",
"      Chenoweth DE, Henderson LW. Complement activation during hemodialysis: laboratory evaluation of hemodialyzers. Artif Organs 1987; 11:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/28\">",
"      Bell, JL, Henderson, LW. Anaphylatoxin mass generated by cuprophane membranes is not influenced by blood flow rate. Kidney Int 1989; 35:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/29\">",
"      Deppish, R, Eberhard, R, et al. Biocompatibility &mdash; Perspectives in 1993. Kidney Int 1994; 45:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/30\">",
"      Dinarello CA. Cytokines: agents provocateurs in hemodialysis? Kidney Int 1992; 41:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/31\">",
"      Hutter JC, Kuehnert MJ, Wallis RR, et al. Acute onset of decreased vision and hearing traced to hemodialysis treatment with aged dialyzers. JAMA 2000; 283:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4295/abstract/32\">",
"      Bellucci A. Shortness of breath and abdominal pain within minutes of starting hemodialysis. Semin Dial 2004; 17:417.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1859 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4295=[""].join("\n");
var outline_f4_12_4295=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1453243052\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF HEMODIALYSIS MEMBRANES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPE A REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TYPE B REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OTHER REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1453243052\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1859\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1859|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/24/38285\" title=\"figure 1\">",
"      Transient neutropenia during HD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/25/15774\" title=\"figure 2\">",
"      C3a concentrations in pts on HD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=related_link\">",
"      Acute complications during hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9911?source=related_link\">",
"      Biochemical mechanisms involved in blood-hemodialysis membrane interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=related_link\">",
"      Clinical consequences of hemodialysis membrane biocompatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7096?source=related_link\">",
"      Reuse of dialyzers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_12_4296="Quinidine: Pediatric drug information";
var content_f4_12_4296=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quinidine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"    see \"Quinidine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/17/23829?source=see_link\">",
"    see \"Quinidine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Quinidine&reg;;",
"     </li>",
"     <li>",
"      BioQuin&reg; Durules&trade;;",
"     </li>",
"     <li>",
"      Novo-Quinidin;",
"     </li>",
"     <li>",
"      Quinate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiarrhythmic Agent, Class I-A",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimalarial Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"      see \"Quinidine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose expressed in terms of the salt: 267 mg of quinidine gluconate = 200 mg of quinidine sulfate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Malaria, treatment (severe, life-threatening): Infants, Children, and Adults: I.V. (",
"     <b>",
"      quinidine gluconate",
"     </b>",
"     ): 10 mg/kg infused over 60-120 minutes, followed by 0.02 mg/kg/minute continuous infusion for &ge;24 hours; alternatively, may administer 24 mg/kg loading dose over 4 hours, followed by 12 mg/kg over 4 hours every 8 hours (beginning 8 hours after loading dose). Change to oral quinine once parasite density is &lt;1% and patient can receive oral medication to complete treatment course; total duration of treatment (quinidine/quinine): 3 days in Africa or South America; 7 days in Southeast Asia; use in combination with doxycycline, tetracycline, or clindamycin; omit quinidine loading dose if patient received &gt;40 mg/kg of quinine in preceding 48 hours or mefloquine within preceding 12 hours (CDC, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Close monitoring, including telemetry, is",
"     <b>",
"      required",
"     </b>",
"     ; if severe cardiac adverse effects occur, infusion rate may need to be decreased or drug temporarily discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Arrhythmias:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Oral (",
"     <b>",
"      quinidine sulfate",
"     </b>",
"     ): Usual: 30 mg/kg/day or 900 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day given in 5 daily doses or 6 mg/kg every 4-6 hours; range: 15-60 mg/kg/day in 4-5 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     I.V. (",
"     <b>",
"      quinidine gluconate",
"     </b>",
"     ): 2-10 mg/kg/dose every 3-6 hours as needed (I.V. route",
"     <b>",
"      not",
"     </b>",
"     recommended)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Oral (",
"     <b>",
"      sulfate",
"     </b>",
"     ): 100-600 mg/dose every 4-6 hours; begin at 200 mg/dose and titrate to desired effect (maximum daily dose: 3-4 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Oral (",
"     <b>",
"      gluconate",
"     </b>",
"     ): 324-972 mg every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Children and Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 75% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Adults: 200 mg supplemental dose posthemodialysis is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Larger loading dose may be indicated; reduce maintenance dose by 50% and monitor serum levels closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as gluconate: 80 mg/mL (10 mL) [equivalent to quinidine base 50 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 200 mg [equivalent to quinidine base 166 mg], 300 mg [equivalent to quinidine base 249 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as gluconate: 324 mg [equivalent to quinidine base 202 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as sulfate: 300 mg [equivalent to quinidine base 249 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with water on an empty stomach, but may administer with food or milk to decrease GI upset; best to administer in a consistent manner with regards to meals; avoid administration with grapefruit juice; swallow extended release tablets whole, do not chew or crush",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: Maximum rate of infusion: 10 mg/minute; maximum concentration: 16 mg/mL; I.V. tubing length should be minimized (quinidine may be significantly adsorbed to polyvinyl chloride tubing)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F216528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Diazepam, milrinone, nesiritide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Heparin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not use discolored parenteral solution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis after cardioversion of atrial fibrillation and/or flutter to maintain normal sinus rhythm; also used to prevent reoccurrence of paroxysmal supraventricular tachycardia, paroxysmal A-V junctional rhythm, paroxysmal ventricular tachycardia, paroxysmal atrial fibrillation, and atrial or ventricular premature contractions (FDA approved in adults);",
"     <b>",
"      Note:",
"     </b>",
"     The use of I.V. quinidine gluconate for these indications has been replaced by more effective/safer antiarrhythmic agents (eg, amiodarone and procainamide); treatment of life-threatening",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     malaria [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       QuiNIDine may be confused with cloNIDine, quiNINE",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F216527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, new or worsened arrhythmia (proarrhythmic effect), hypotension, palpitation, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (modest prolongation is common, however, excessive prolongation is rare and indicates toxicity), syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, incoordination, lightheadedness, nervousness, sleep disturbance, syncope, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, bitter taste, diarrhea, nausea, stomach cramping, upper GI distress, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal pigmentation, acute psychotic reactions, agranulocytosis, angioedema, arthralgia, bronchospasm, cerebral hypoperfusion (possibly resulting in ataxia, apprehension, and seizure), cholestasis, confusion, CPK increased, delirium, depression, drug-induced lupus-like syndrome, eczematous dermatitis, esophagitis, exacerbated bradycardia (in sick sinus syndrome), exfoliative rash, fever, flushing, granulomatous hepatitis, hallucinations, hearing impaired, heart block, hemolytic anemia, hepatotoxic reaction (rare),  lichen planus, livedo reticularis, lymphadenopathy, melanin pigmentation of the hard palate, myalgia, mydriasis, nephropathy, optic neuritis, pancytopenia, paradoxical increase in ventricular rate during atrial fibrillation/flutter, photosensitivity, pneumonitis, pruritus, psoriaform rash, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (excessive), respiratory depression, sicca syndrome, tachycardia, thrombocytopenia, thrombocytopenic purpura, torsade de pointes, urticaria, uveitis, vascular collapse, vasculitis, ventricular fibrillation, ventricular tachycardia, vertigo, visual field loss",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Cinchonism, a syndrome which may include tinnitus, high-frequency hearing loss, deafness, vertigo, blurred vision, diplopia, photophobia, headache, confusion, and delirium has been associated with quinidine use. Usually associated with chronic toxicity, this syndrome has also been described after brief exposure to a moderate dose in sensitive patients. Vomiting and diarrhea may also occur as isolated reactions to therapeutic quinidine levels.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to quinidine, any component, or cinchona derivatives; patients who have a history of thrombocytic purpura during prior therapy with quinidine or quinine; patients with complete A-V block with an A-V junctional or idioventricular pacemaker; patients with intraventricular conduction defects (marked widening of QRS complex); patients who might be adversely affected by anticholinergic agents (eg, myasthenia gravis)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with myocardial depression, sick sinus syndrome, cardiac glycoside intoxication, hepatic and/or renal insufficiency; hemolysis may occur in patients with G-6-PD deficiency; quinidine-induced hepatotoxicity, including granulomatous hepatitis, increased serum AST and alkaline phosphatase concentrations, and jaundice may occur; use with caution in nursing women; adjust dose with severe renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiarrhythmic drugs have not been shown to enhance survival in nonlife-threatening ventricular arrhythmias and may increase mortality; the risk is greatest with structural heart disease. Quinidine may increase mortality in treatment of atrial fibrillation/flutter",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Quinidine prolongs the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval, which may lead to torsade de pointes; risk increased by bradycardia, hypokalemia, hypomagnesemia, or high serum levels of quinidine. May increase ventricular response rate in patients with atrial fibrillation or flutter; control AV conduction before initiating. May cause syncope, most likely due to ventricular tachycardia or fibrillation; syncope may subside spontaneously, but occasionally may be fatal; discontinue quinidine if syncope occurs",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F216517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP2D6 (strong), CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia). Management: Risk of QTc prolongation and Torsades de Pointes may be increased; consider alternative therapy when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of QuiNIDine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of QuiNIDine. Management: Itraconazole, voriconazole, and posaconazole are specifically contraindicated with quinidine.  Use of quinidine with any azole antifungal may require quinidine dose adjustment and should be done with caution and close monitoring.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: QuiNIDine may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): QuiNIDine may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Felodipine; Nisoldipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of QuiNIDine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: QuiNIDine may increase the serum concentration of Cardiac Glycosides.  Management: Upon quinidine initiation, consider reducing cardiac glycoside dose by 25% to 50%, with continued monitoring of glycoside serum concentrations and clinical response until the quinidine reaches steady state (5-10 days).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of QuiNIDine. Management: Consider alternatives to cimetidine. If the combination cannot be avoided, monitor for increased quinidine concentrations/toxicity with cimetidine initiation/dose increase, or decreased concentrations/effects with cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May enhance the QTc-prolonging effect of QuiNIDine. Crizotinib may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: QuiNIDine may increase the serum concentration of Dabigatran Etexilate.  Management: Canadian (but not U.S.) prescribing information recommends dosing dabigatran 2 hours prior to quinidine, and limiting dabigatran VTE prevention dose post hip/knee replacement to 150 mg/day in patients receiving quinidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: QuiNIDine may increase the serum concentration of Dalfampridine.  Management: Recommendations differ significantly between international labelings in regards to the concomitant use of dalfampridine (referred to as fampridine in Canada) and quinidine. Consult appropriate product labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: QuiNIDine may increase the serum concentration of Dextromethorphan.  Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydrocodeine: QuiNIDine may diminish the analgesic effect of Dihydrocodeine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: May enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Haloperidol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrocodone: QuiNIDine may decrease serum concentrations of the active metabolite(s) of Hydrocodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kaolin: May decrease the serum concentration of QuiNIDine. Management: Consider separating doses of kaolin and quinidine by at least 2 hours in order to reduce the risk of interaction. Monitor for decreased therapeutic effects of quinidine if kaolin is simultaneously coadministered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: May enhance the QTc-prolonging effect of QuiNIDine. Management: Consider alternatives to quinidine in patients with acute lurasidone overdose.  If quinidine treatment cannot be avoided, monitor for excessive QTc interval prolongation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of QuiNIDine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: QuiNIDine may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased.  Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of quinidine when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QuiNIDine. Mifepristone may increase the serum concentration of QuiNIDine. Management: Avoid quinidine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: QuiNIDine may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May diminish the therapeutic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: QuiNIDine may enhance the QTc-prolonging effect of Propafenone. QuiNIDine may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the adverse/toxic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of QuiNIDine. Management: Consider alternatives to combination treatment with quinidine and rifampin due to large potential decreases in quinidine concentrations. Monitor for decreased quinidine concentrations/effects with initiation/dose increase of any rifamycin derivative.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of QuiNIDine. Fluvoxamine appears to be the only SSRI of concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline; Vilazodone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of QuiNIDine. Specifically, sucralfate may decrease the absorption of quinidine. Management: Administer quinidine at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May enhance the adverse/toxic effect of QuiNIDine. Telaprevir may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: QuiNIDine may enhance the hypotensive effect of Verapamil. Verapamil may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): QuiNIDine may enhance the anticoagulant effect of Vitamin K Antagonists. Note that the INR/PT might be unchanged in the face of increased bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excessive intake of fruit juices or vitamin C may decrease urine pH and result in increased clearance of quinidine with decreased serum concentration; alkaline foods may result in increased quinidine serum concentrations; food has a variable effect on absorption of extended release formulation. Grapefruit juice delays absorption of quinidine, decreases quinidine clearance, inhibits cytochrome P450 CYP3A4 mediated metabolism of quinidine to 3-hydroxyquinidine (major metabolite of quinidine), and significantly decreases the AUC of 3-hydroxyquinidine (although the clinical significance of the quinidine-grapefruit juice interaction is unknown, grapefruit juice should be avoided). A decrease in dietary salt intake may increase serum quinidine concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13386486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Quinidine crosses the placenta and can be detected in the amniotic fluid, cord blood, and neonatal serum. Quinidine is indicated for use in the treatment of severe malaria infection in pregnant women (CDC, 2011; Smereck, 2011) and has also been used to treat arrhythmias in pregnancy when other agents are ineffective (European Society of Cardiology, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelet count, liver and renal function tests. Serum concentrations should be routinely performed during long-term administration. Continuously monitor blood pressure and ECG (for widening QRS complex and lengthening of QT",
"     <sub>",
"      c",
"     </sub>",
"     interval) and periodically monitor blood glucose for hypoglycemia with I.V. use.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1055254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Optimal therapeutic level is method dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: 2-7 mcg/mL (SI: 6.2-15.4 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;8 mcg/mL (SI: &gt;18 micromoles/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Class IA antiarrhythmic with anticholinergic, local anesthetic, and mild negative inotropic effects; depresses phase 0 of the action potential; decreases myocardial excitability, conduction velocity, and myocardial contractility by decreasing sodium influx during depolarization and potassium efflux in repolarization; also reduces calcium transport across cell membrane",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 2-3.5 L/kg, decreased V",
"     <sub>",
"      d",
"     </sub>",
"     with CHF, malaria; increased V",
"     <sub>",
"      d",
"     </sub>",
"     with cirrhosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein-binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 60% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 80% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Decreased protein binding with cyanotic congenital heart disease, cirrhosis, or acute MI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver (50% to 90%) to inactive compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gluconate: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sulfate: 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, plasma (increased half-life with cirrhosis and CHF):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2.5-6.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine (15% to 25% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Slightly dialyzable (5% to 20%) by hemodialysis; not removed by peritoneal dialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/17/23829?source=see_link\">",
"      see \"Quinidine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if fever, rash, unusual bruising or bleeding, visual disturbances, or ringing in the ears occurs; avoid grapefruit juice; avoid excessive intake of fruit juices or vitamin C. May rarely cause photosensitivity reactions; avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); use a sunscreen; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1055261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of extended release products is not recommended in children. Formation of a concretion of tablets or bezoar in the stomach has been reported following tablet ingestion by a 16-month old infant; diagnostic or therapeutic endoscopy may be required in patients with massive overdose and prolonged elevated serum quinidine concentrations",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F216482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 10 mg/mL oral liquid preparation may be made with tablets and one of three different vehicles (cherry syrup, a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;, or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;). Crush six 200 mg tablets in a mortar and reduce to a fine powder. Add 15 mL of the chosen vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label \"shake well\" and \"protect from light\". Stable for 60 days when stored in amber plastic prescription bottles in the dark at room temperature or refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV and Erickson MA, \"Stability of Bethanechol Chloride, Pyrazinamide, Quinidine Sulfate, Rifampin, and Tetracycline in Extemporaneously Compounded Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1998, 55(17):1804-9.",
"     <span class=\"pubmed-id\">",
"      9775343",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4296/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Guidelines for Treatment of Malaria in the United States, 2009.\" Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pickoff AS, Singh S, and Gelband H,",
"      <i>",
"       The Medical Management of Cardiac Arrhythmias in Cardiac Arrhythmias in the Neonate, Infant and Child",
"      </i>",
"      , Roberts NK and Gelband H, ed, Norwalk, CT: Appleton-Century-Crofts, 1983.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Szefler SJ, Pieroni DR, Gingell RL, et al, \"Rapid Elimination of Quinidine in Pediatric Patients,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1982, 70(3):370-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/12/4296/abstract-text/7110810/pubmed\" id=\"7110810\" target=\"_blank\">",
"        7110810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12755 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4296=[""].join("\n");
var outline_f4_12_4296=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709382\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216499\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055252\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055245\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216475\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216460\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055256\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216528\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055248\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055255\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216530\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216527\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055260\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055244\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055243\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216517\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216469\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055263\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216471\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13386486\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055251\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055254\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055242\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055259\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055250\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055261\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216482\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12755\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12755|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=related_link\">",
"      Quinidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/17/23829?source=related_link\">",
"      Quinidine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_12_4297="Mendelian susceptibility to mycobacterial diseases (MSMD)";
var content_f4_12_4297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mendelian susceptibility to mycobacterial diseases (MSMD)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/12/4297/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/12/4297/contributors\">",
"     Gulbu Uzel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/12/4297/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/12/4297/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/12/4297/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/12/4297/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/12/4297/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within the last decade, systemic infections with nontuberculous mycobacteria (NTM) have led to the discovery of important genetic defects in the mononuclear",
"    <span class=\"nowrap\">",
"     phagocyte/Th1",
"    </span>",
"    T cell pathway. As a result, Mendelian susceptibility to mycobacterial diseases (MSMD) has been established (MIM# 209950) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/1\">",
"     1",
"    </a>",
"    ]. Today, as new genes and genetic defects become added to this list, our understanding of critical signaling pathways that are responsible for killing of mycobacterium has become clearer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25288?source=see_link\">",
"     \"Pathogenesis of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Biology of the interferon gamma pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Host defense against pathogenic (M. tuberculosis, TB) and nontuberculous (atypical) mycobacteria (M. fortuitum, M. chelonae, M. abscessus, M. avium complex, M. kansasii, M. simiae and M. marinum), as well as salmonellae, depends heavily upon the functional integrity of mononuclear phagocytes and their interaction with T cells. Interferon gamma (IFN-gamma), a pleiotropic Th1-type cytokine, is a principal factor in the elimination of both TB and the nontuberculous group of mycobacteria (NTM) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/2\">",
"     2",
"    </a>",
"    ]. It is also essential in the control of certain bacterial, parasitic, and viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25288?source=see_link\">",
"     \"Pathogenesis of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Macrophages infected with mycobacteria produce the cytokine interleukin 12 (IL-12, which is a heterodimer of IL-12 p40 plus IL-12 p35) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/10\">",
"     10",
"    </a>",
"    ]. IL-12 stimulates T cells and Natural Killer (NK) cells via its heterodimeric receptor (IL-12Rbeta1 plus IL-12Rbeta2). In response to stimulation with IL-12, activated T cells and NK cells produce IFN-gamma (",
"    <a class=\"graphic graphic_figure graphicRef50107 \" href=\"UTD.htm?5/59/6070\">",
"     figure 1",
"    </a>",
"    ). IFN-gamma binds to its receptor, IFN-gamma-R1, with high affinity, leading to receptor dimerization. This is followed by aggregation of two accessory chains (IFN-gammaR2) with the receptor complex.",
"   </p>",
"   <p>",
"    Transphosphorylation of JAK1 and JAK2, the Janus kinases that are constitutively associated with IFN-gamma-R1 and IFN-gamma-R2 respectively, occurs next [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/11\">",
"     11",
"    </a>",
"    ]. The subsequent signaling event is the tyrosine phosphorylation of the latent cytosolic transcription factor STAT1, which is followed by homodimerization and translocation to the nucleus as a complex.",
"   </p>",
"   <p>",
"    This initiates the transcription of IFN-gamma-regulated genes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. One of the results of IFN-gamma activation on phagocytes is the production of tumor necrosis factor alpha (TNF-alpha) and further up regulation of IL-12 production. At this point, IFN-gamma also promotes mycobacterial killing, for which the mechanism remains unknown.",
"   </p>",
"   <p>",
"    Patients with defects in IFN-gamma-R1 or IFN-gamma-R2, IL-12 receptor beta1, IL-12 p40, STAT1, and IRF8 have been identified. In this review, the clinical features, diagnostic tools and available treatment options for these patients will be discussed. Defects in two other genes have been identified that cause X-linked MSMD, IKBKG (encodes nuclear factor kappa B essential modulator, NEMO) and CYBB (encodes gp91phox). NEMO deficiency is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H18#H18\">",
"     \"Combined immunodeficiencies\", section on 'Defects of NF-kappa-B regulation'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTERFERON GAMMA RECEPTOR DEFICIENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in both IFN-gamma-R chains have been identified and characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/3-8,14,15\">",
"     3-8,14,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interferon gamma receptor 1 deficiency (",
"      <em>",
"       IFNGR1",
"      </em>",
"      ; gene encoded on chromosome 6q23-q24, MIM# 107470)",
"     </li>",
"     <li>",
"      Interferon gamma receptor 2 deficiency (",
"      <em>",
"       IFNGR2",
"      </em>",
"      , gene encoded on chromosome 21q22.1-q22.2, MIM# 147569)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Autosomal recessive defects in",
"    <em>",
"     IFNGR1",
"    </em>",
"    and",
"    <em>",
"     IFNGR2",
"    </em>",
"    result in complete or partial deficiencies. Autosomal dominant inheritance is also observed for IFNGR1 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Autosomal recessive complete IFN-gamma receptor deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal recessive",
"    <strong>",
"     complete",
"    </strong>",
"    IFN-gamma-R1 or IFN-gamma-R2 deficient patients tend to develop severe disseminated mycobacterial disease in infancy or early childhood, requiring continuous antimycobacterial therapy. In one large series, affected patients had frequent mycobacterial disease episodes (mean of 19 per 100 person-years more episodes), more disseminated disease (mean of four organs per infection), and shorter mean disease-free intervals (mean 1.6 years) compared to patients with autosomal dominant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mode of presentation and the particular mycobacterial strain depends upon geographic location and whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/30/28135?source=see_link\">",
"     bacillus Calmette-Guerin (BCG) vaccine",
"    </a>",
"    is routinely administered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In countries that administer BCG vaccine routinely, the outcome is usually disseminated infection with the vaccine strain [",
"      <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In countries where the first encounter with NTM is via environmental exposure, infection with M. avium, M. fortuitum, M. chelonae, and M. smegmatis ensues. The first encounter is usually observed in very young children (average age of 3.1 years in one large series [",
"      <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/16\">",
"       16",
"      </a>",
"      ]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The typical histopathologic feature is failure to form well-circumscribed tuberculoid granulomas. Although infection with mycobacteria and salmonella have been predominantly associated with these genetic defects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/16\">",
"     16",
"    </a>",
"    ], the phenotype has been expanded to include increased susceptibility to cytomegalovirus, respiratory syncytial virus, varicella-zoster virus, parainfluenza virus, and Listeria monocytogenes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/8,9,17\">",
"     8,9,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These autosomal recessive mutations in IFN-gamma-R1 or IFN-gamma-R2, which lead to complete loss of protein expression, have been mapped to the extracellular domains of the receptor proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. In autosomal recessive complete IFN-gamma-R1 deficiency, flow cytometric analyses of peripheral blood mononuclear cells (PBMCs) show significantly decreased or absent cell surface expression of IFN-gamma-R1; this also means that signaling via the IFN-gamma-R is defective, which is detected via absent intracellular staining for phosphorylated STAT1 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis is established by flow cytometric evaluation of cell surface receptor expression on monocytes and lymphocytes as well as examining signaling either by intracellular staining (lack of STAT1 phosphorylation in response to IFN-gamma) or western blot. Detection of the mutation at the molecular level confirms the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=see_link\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to interferon gamma receptor deficiencies, the differential diagnosis in patients with disseminated NTM infections includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Human immunodeficiency virus (HIV)",
"      <span class=\"nowrap\">",
"       infection/acquired",
"      </span>",
"      immune deficiency syndrome (AIDS)",
"     </li>",
"     <li>",
"      Idiopathic CD4 lymphocytopenia",
"     </li>",
"     <li>",
"      Other T cell immunodeficiencies, such as severe combined immunodeficiency (SCID), ectodermal dysplasia with immunodeficiency (EDID) due to mutations in NF-kappa B essential modifier (NEMO), and rarely chronic granulomatous disease (CGD)",
"     </li>",
"     <li>",
"      GATA2 deficiency (see",
"      <a class=\"local\" href=\"#H3663155\">",
"       'GATA2 deficiency (MonoMAC syndrome)'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IL-12 and IL-12 receptor beta-1 defects, as well as STAT1 defects should also be considered. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'IL-12 receptor beta1 deficiency'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'STAT1 deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Since unexpressed receptors lead to a failure to respond to IFN-gamma, cytokine replacement therapy has limited efficacy among patients with autosomal recessive complete defects of IFN-gamma-R1 and IFN-gamma-R2. The group at the US National Institutes of Health (NIH) clinical center has instead administered escalating doses of IFN-alpha, along with antimycobacterial chemotherapy to patients with complete IFN-gamma-R1 defect. This regimen stabilized the mycobacterial overload and initiated the granuloma formation process. Signaling through the IFN-alpha receptor via flow-cytometric assays following in-vivo administration of IFN-alpha was observed. The rationale has been to override the defective IFN-gamma receptor with a cytokine, in this case with IFN-alpha, which would turn on similar downstream transcription factors and genes as IFN-gamma while mobilizing",
"    <span class=\"nowrap\">",
"     monocytes/macrophages",
"    </span>",
"    to the periphery to be targeted by IFN-alpha.",
"   </p>",
"   <p>",
"    Aggressive treatment with antimycobacterial antibiotics remains as the single accepted method for the management of patients with this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Several patients with complete IFN-gamma-R deficiencies have been transplanted in Europe and the United States. Complications have been fatal GVHD, severe generalized granulomatous response, failure to clear infection, and Gram-negative sepsis.",
"   </p>",
"   <p>",
"    One multi-institutional survey of eight patients who received 11 hematopoietic cell transplants (HCT) noted that four died and minimal to no engraftment was observed in two [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/21\">",
"     21",
"    </a>",
"    ]. The only two individuals in full remission five years after the procedure were the only patients administered non-T cell depleted grafts from an HLA-identical sibling after a fully ablative regimen. Subsequently, another patient was successfully transplanted after myeloablative conditioning, in this case with an unrelated donor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/22\">",
"     22",
"    </a>",
"    ]. Taken together, these observations suggest that the success of HCT may be related to the conditioning regimen.",
"   </p>",
"   <p>",
"    It is also possible that the success of HCT is related to how well mycobacterial infection is controlled before transplantation, although one patient was successfully transplanted despite having active M. fortuitum infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autosomal dominant IFN-gamma-R1 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;More common than the autosomal recessive forms of IFN-gamma-R deficiency is the autosomal dominant IFN-gamma-R1 deficiency. A small deletion hot spot in the intracellular domain of IFN-gamma-R1 has been identified as the cause for the autosomal dominant susceptibility to mycobacterial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/24\">",
"     24",
"    </a>",
"    ]. In this defect, the mutation is just beyond the transmembrane segment. The genetic lesion can be one of four independent mutation events around base 814 of the IFN-gamma-R1 cDNA, a 4 bp deletion (collectively referred to as 818del4) leading to a frame shift and premature truncation of IFN-gamma-R1 and eliminating the Jak1 and STAT1 binding sites. In addition, the receptor recycling domain, which is next to the Jak1 binding site, is also removed.",
"   </p>",
"   <p>",
"    Loss of the receptor recycling domain severely impairs the normal removal and recycling of the receptor from the cell surface. Since the JAK1 and STAT1 binding motifs and the receptor-recycling domain are deleted, mutant chains with intact extracellular domains can still bind IFN-gamma, but fail to transduce the signal and do not get recycled. Overexpressed, abundant mutant receptors compete with wild-type receptors at the cell surface for binding IFN-gamma. The combination of preserved binding to its ligand, absent signaling, and impaired recycling forms the",
"    <strong>",
"     dominant negative",
"    </strong>",
"    effect [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/7,24\">",
"     7,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Flow cytometric analysis of monocytes from affected patients demonstrates a three to fivefold increase in IFN-gamma-R1 expression compared with healthy control cells. However, STAT1 phosphorylation following in-vitro stimulation with IFN-gamma is minimal or undetectable even at 100-fold higher concentrations of IFN-gamma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=see_link\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation is usually later in childhood or in adolescence. Patients with this genotype are from diverse ethnic backgrounds, yet present with severe localized or disseminated BCG or NTM infections, histoplasmosis, or salmonellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/7,25-27\">",
"     7,25-27",
"    </a>",
"    ]. Almost all patients with autosomal dominant IFN-gamma-R deficiency develop multifocal NTM osteomyelitis, a manifestation that has become the hallmark for this genotype. In one series, 79 percent had NTM osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histology reveals paucibacillary and more mature looking granulomas. This finding is similar to those of partial IFN-gamma-R1 deficiency (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Autosomal recessive partial IFN-gamma receptor deficiencies'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Patients' response to antimycobacterial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/19,20\">",
"     19,20",
"    </a>",
"    ] and adjunctive IFN-gamma therapy given at relatively higher dose (usually two to three times the standard dose for chronic granulomatous disease [CGD] based upon the author&rsquo;s personal experience) is much more favorable than those in patients with complete IFN-gamma-R1 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/6\">",
"     6",
"    </a>",
"    ]. IFN-gamma may be dosed initially at 50",
"    <span class=\"nowrap\">",
"     mcg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (or 1 million",
"    <span class=\"nowrap\">",
"     IU/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    for patients whose",
"    <a class=\"external\" href=\"file://www.rxlist.com/script/main/art.asp?articlekey=39851\">",
"     body surface area",
"    </a>",
"    is greater than 0.5 m",
"    <sup>",
"     2",
"    </sup>",
"    and 1.5",
"    <span class=\"nowrap\">",
"     mcg/kg/dose",
"    </span>",
"    for patients whose body surface area is equal to or less than 0.5 m",
"    <sup>",
"     2",
"    </sup>",
"    , which is the standard CGD dose. The dose can then be escalated gradually based upon patients&rsquo; tolerance and response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Autosomal recessive partial IFN-gamma receptor deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare partial defects in both IFN-gamma-R1 and IFN-gamma-R2, in which IFN-gamma signal transduction is impaired but not abolished, have also been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/14,28,29\">",
"     14,28,29",
"    </a>",
"    ]. These defects are due to homozygous recessive missense mutations causing amino acid replacements in the extracellular domains. The receptor is expressed on the cell surface and the response to gamma is diminished, but not totally abolished, at the cellular level.",
"   </p>",
"   <p>",
"    The clinical phenotype is usually milder than that of patients with complete defects. Affected patients can have normal granuloma formation and tend to present later in life with rather limited disease.",
"   </p>",
"   <p>",
"    Partial interferon gamma receptor defect should be considered in children or adults with mycobacterial infections in whom the disease is not as disseminated as seen in complete defects and in whom normal granuloma formation is evident. Diagnosis is established by detection of the mutation. Flow cytometric evaluation of the receptor may or may not be helpful since the dysfunctional receptor may still be expressed on the cell surface at normal amounts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=see_link\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As compared with complete defects, Mycobacterial infections in those with partially functional interferon gamma receptor defects can be treated more successfully with antibiotics, with or without added IFN-gamma. A trial of antimycobacterial antibiotic combination therapy alone may therefore lead to successful elimination of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IL-12 RECEPTOR BETA1 DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the gene encoding the IL-12 receptor beta1 (IL-12Rbeta1) subunit (",
"    <em>",
"     IL12RB1",
"    </em>",
"    , encoded on chromosome 19p13.1, MIM# 601604) have been identified in patients with disseminated nontuberculous mycobacterial and Salmonella infections in the setting of IL-12 unresponsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/1,30-37\">",
"     1,30-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All reported patients are homozygous for autosomal recessive mutations, while the carriers are clinically healthy with normal IL-12 signaling and IFN-gamma production patterns. Mutations are in the extracellular domain of the IL-12Rbeta1, thereby leading to premature stop codons and precluding the surface expression of this protein. As a result of defective IL-12R signaling, IFN-gamma secretion by otherwise healthy T cells and NK cells is impaired.",
"   </p>",
"   <p>",
"    These patients develop disseminated Salmonella and nontuberculous mycobacterial infections or disseminated BCG infection following inoculation with the vaccine. Granulomas are well contained and well organized.",
"   </p>",
"   <p>",
"    In an international study of 141 patients, the first infection occurred on average at 2.4 years of age in the 102 probands and was caused by BCG (64 percent), nontyphoidal salmonella (22 percent), nontuberculous mycobacteria (9 percent), or TB (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/38\">",
"     38",
"    </a>",
"    ]. Mild chronic mucocutaneous candidiasis was reported in 23 percent of all patients. BCG disease was inversely associated with subsequent infection with nontuberculous mycobacteria. Twenty-seven percent of genetically affected siblings were asymptomatic. The overall mortality rate was around 30 percent, with a mean age at last follow-up visit of 12.7 years (range 0.5 to 46.4 years). Patients with nontuberculous mycobacteria infection had the worst prognosis.",
"   </p>",
"   <p>",
"    Diagnostic findings are the failure to detect IL-12Rbeta1 on T-lymphoblasts, and defective intracellular STAT4 phosphorylation in response to IL-12 stimulation. IFN-gamma therapy, at the standard doses used in chronic granulomatous disease (CGD) as described above, may provide benefit in patients for whom antimycobacterials alone have been incompletely successful. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Autosomal dominant IFN-gamma-R1 deficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IL-12P40 DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A kindred with loss of function autosomal recessive mutation in the gene encoding the p40 subunit of IL-12 (",
"    <em>",
"     IL12B",
"    </em>",
"    , encoded on chromosome 5q31.1-33.1, MIM# 161561) was reported in 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/39\">",
"     39",
"    </a>",
"    ]. Six other kindreds were subsequently reported in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/40\">",
"     40",
"    </a>",
"    ]. Neither the IL-12p40 subunit nor the IL-12p70 heterodimer were detectable in these patients. The lymphocytes secreted a reduced amount of IFN-gamma, which could be corrected with recombinant IL-12 in vitro.",
"   </p>",
"   <p>",
"    This is a milder clinical phenotype than complete IFN-gamma-R1 or IFN-gamma-R2 deficiencies since residual, IL-12 independent IFN-gamma secretion pathways persist, as reflected by patients' capacity to form organized granulomata.",
"   </p>",
"   <p>",
"    Treatment of choice is antibiotics and subcutaneous IFN-gamma, as described above for IL-12Rbeta1 deficiency, which is usually successful in controlling the infection. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Autosomal dominant IFN-gamma-R1 deficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     STAT1 DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signal transducer and activator of transcription 1 (",
"    <em>",
"     STAT1",
"    </em>",
"    , encoded on chromosome 2q32.2-q32.3, MIM# 600555) is a critical signal transducer for both the IFN-gamma receptor and",
"    <span class=\"nowrap\">",
"     IFN-alpha/beta",
"    </span>",
"    receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/1\">",
"     1",
"    </a>",
"    ]. Following IFN-gamma stimulation, STAT1 phosphorylates and homodimerizes to form the gamma-activating-factor (GAF). In contrast, following",
"    <span class=\"nowrap\">",
"     IFN-alpha/beta",
"    </span>",
"    stimulation, STAT1 combines with both STAT2 and p48, a cytoplasmic protein, and forms the interferon-stimulated gene factor 3 (ISGF3).",
"   </p>",
"   <p>",
"    Two types of partial STAT1 deficiency with autosomal dominant inheritance have been reported. The first type, due to a heterozygous point mutation in the",
"    <em>",
"     STAT1",
"    </em>",
"    gene, was described in two unrelated kindreds [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/41\">",
"     41",
"    </a>",
"    ]. This mutation results in hindered phosphorylation of STAT1 at tyrosine 701, leading to obstruction of STAT1 dimerization and nuclear translocation as GAF and selective impairment the antimycobacterial activity of IFN-gamma. However, this autosomal dominant mutation does not interfere with ISGF3 nuclear translocation, sparing",
"    <span class=\"nowrap\">",
"     IFN-alpha/beta",
"    </span>",
"    mediated antiviral activity.",
"   </p>",
"   <p>",
"    One patient with this genotype had disseminated BCG infection with tuberculous granulomas following immunization and the other had disseminated M. avium infection as a child. The clinical and cellular phenotypes of these patients were similar to those of patients with partial recessive IFN-gamma-R deficiency. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Autosomal recessive partial IFN-gamma receptor deficiencies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The second type of autosomal dominant partial STAT1 deficiency is due to mutations in the STAT1 DNA-binding domain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/42\">",
"     42",
"    </a>",
"    ]. Two different mutant alleles have been identified. As with the first type, IFN-gamma-induced GAF-mediated immunity is impaired, but",
"    <span class=\"nowrap\">",
"     IFN-alpha/beta-induced",
"    </span>",
"    ISGF3-mediated immunity is maintained. The clinical phenotype is one of increased susceptibility to mycobacterial infection.",
"   </p>",
"   <p>",
"    In contrast, autosomal recessive complete STAT1 deficiency is a severe form of innate immunodeficiency that leads to increased susceptibility to both mycobacterial and viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Three different mutant alleles have been identified. STAT1 protein is not expressed in these patients. The three unrelated patients described with this deficiency all developed disseminated BCG vaccine-acquired infection. All died in infancy, one from herpes simplex encephalitis, another from an unidentified viral illness, and the third died from multiorgan failure secondary to fulminant Epstein-Barr virus infection three months after hematopoietic cell transplantation.",
"   </p>",
"   <p>",
"    A partial form of autosomal recessive STAT1 deficiency has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. This form of STAT1 deficiency is caused by a hypomorphic missense mutation that leads to impaired splicing of STAT1 mRNA. The misspliced mRNA is not translated into a stable protein. However, the allele is hypofunctional, because residual full-length mRNA is produced and translated, resulting in low levels of functional STAT1. GAF-mediated immunity is more impaired than ISGF3-mediated immunity. The two siblings identified with this defect both presented with recurrent and disseminated Salmonella infections. One patient also suffered from recurrent herpes simplex virus infections. In both cases the intracellular bacterial and viral infections were severe but curable.",
"   </p>",
"   <p>",
"    In patients with STAT1 deficiency, the mycobacterial infections can be treated with antibiotics and IFN-gamma at the standard chronic granulomatous disease (CGD) prophylaxis doses. Bone marrow transplantation is not indicated, except for autosomal recessive complete STAT1 deficiency, which appears to be lethal in the first year of life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=see_link&amp;anchor=H6#H6\">",
"     \"Chronic granulomatous disease: Treatment and prognosis\", section on 'Immunomodulatory therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autosomal dominant heterozygous gain of function (GAF) mutations in the coiled or DNA binding domains of STAT1 lead to chronic mucocutaneous candidiasis (CMCC). These patients have an increased incidence for autoimmunity and cancer, but do not have an increased incidence of mycobacterial disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=see_link&amp;anchor=H8501601#H8501601\">",
"     \"Chronic mucocutaneous candidiasis\", section on 'Autosomal dominant CMCC'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1016484\">",
"    <span class=\"h1\">",
"     IRF8 DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon regulatory factor 8 (",
"    <em>",
"     IRF8",
"    </em>",
"    , encoded on 16q24.1) is a transcription factor present in mononuclear phagocytes that regulates expression of IFN-alpha and IFN-beta response genes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. It is involved in defenses against intracellular pathogens, including several aspects of myeloid cell function, such as granulocyte and macrophage differentiation and dendritic cell development. It is crucial for activation of antimycobacterial defenses via production of IL-12 in response to IFN&gamma;. It is thought to be a key regulator for early response in myeloid cells, including phagosome maturation, antigen processing, and antigen presentation.",
"   </p>",
"   <p>",
"    Two types of IRF8 deficiency have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/50\">",
"     50",
"    </a>",
"    ]. The autosomal recessive form (due to homozygous K108E mutations) leads to a complete absence of circulating monocytes and dendritic cells. One patient identified with this genotype presented in early infancy with disseminated BCG infection and oral candidiasis.",
"   </p>",
"   <p>",
"    The milder autosomal dominant form (due to heterozygous T80A mutation) causes selective depletion of circulating dendritic cells. Two patients with this genotype had disseminated BCG disease in early childhood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3663155\">",
"    <span class=\"h1\">",
"     GATA2 DEFICIENCY (MonoMAC SYNDROME)",
"    </span>",
"    &nbsp;&mdash;&nbsp;GATA2 (located at 3q21.3), an early hematopoietic transcription factor active in myeloid development, is defective in MonoMAC syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Haploinsufficiency of",
"    <em>",
"     GATA2",
"    </em>",
"    leads to the syndrome of monocytopenia and mycobacterial disease (MonoMAC), which is characterized by late childhood or adult onset of disseminated nontuberculous mycobacterial disease or disseminated fungal disease. Hemograms in these patients are remarkable for absolute circulating monocytopenia, NK cell cytopenia, and B cell lymphopenia. However, tissue macrophages and plasma cells are present and immunoglobulin levels are normal to elevated. This syndrome has also been called dendritic cell, monocyte, and B and NK lymphoid deficiency (DCML deficiency).",
"   </p>",
"   <p>",
"    Other infections seen in this syndrome are human papillomavirus infections, molluscum contagiosum, histoplasmosis, and aspergillosis. Progressive pulmonary alveolar proteinosis is a common feature, as are cytogenetic abnormalities in bone marrow (eg, trisomy 8 and monosomy 7). Other presentations of this syndrome include aplastic anemia, acute myelogenous leukemia, and chronic myelomonocytic leukemia.",
"   </p>",
"   <p>",
"    The diagnosis is suspected based upon the type of infections and the abnormal hematologic picture. Looking at absolute monocyte numbers can aid in making the diagnosis of this syndrome. Sequencing of",
"    <em>",
"     GATA2",
"    </em>",
"    leads to definitive diagnosis.",
"   </p>",
"   <p>",
"    Hematopoietic cell transplantation has been performed successfully in several patients with GATA2 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11422897\">",
"    <span class=\"h1\">",
"     OTHER DEFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NEMO deficiency, or ectodermal dysplasia with immunodeficiency (ED-ID), is a defect outside of the interferon gamma pathway that may lead to disseminated mycobacterial infections in addition to bacterial and viral infections. NEMO deficiency is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H18#H18\">",
"     \"Combined immunodeficiencies\", section on 'Defects of NF-kappa-B regulation'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Mutations in CYBB, the gene encoding gp91phox, typically lead to X-linked chronic granulomatous disease (CGD). An impaired respiratory burst in phagocytes (neutrophils, monocytes, and macrophages) predisposes patients with CGD to infections with certain bacteria and fungi, including less frequently reported disseminated BCG, atypical mycobacterial, and M. tuberculosis infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=see_link\">",
"     \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A specific mutation in CYBB was identified that only predispose to MSMD rather than the types of infections commonly seen in patients with CGD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/55\">",
"     55",
"    </a>",
"    ]. The seven affected patients from two kindreds in this report presented with recurrent or disseminated tuberculous mycobacterial disease (six with BCG disease and one, who had not been vaccinated with BCG, with tuberculosis). These patients had normal in vitro oxidative burst (by dihydrorhodamine assay and superoxide production), unlike patients with CYBB mutations that have the CGD phenotype. The oxidative burst was defective in macrophages only, rather than all phagocytes, hence the different phenotype. The role of gp91phox in NADPH oxidase is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=see_link&amp;anchor=H2#H2\">",
"     \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H673461\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated mycobacterial infections have been reported in the setting of high titers of neutralizing anti-interferon gamma antibodies. All reported patients are adults of Asian origin and have adult onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Some patients with these autoantibodies to interferon gamma present with other opportunistic infections (eg,",
"    <em>",
"     Cryptococcus neoformans",
"    </em>",
"    ,",
"    <em>",
"     Histoplasma capsulatum",
"    </em>",
"    , and",
"    <em>",
"     Penicillium marneffei",
"    </em>",
"    ), salmonellosis, or severe varicella-zoster virus infection, with or without nontuberculous mycobacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/58\">",
"     58",
"    </a>",
"    ]. No familial clustering has been reported. HIV infection and idiopathic CD4 lymphocytopenia should also be excluded in patients presenting with these infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30009?source=see_link\">",
"     \"Idiopathic CD4+ lymphocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with late onset disseminated mycobacterial infection, investigations for anti-interferon gamma antibodies with neutralizing activity should be performed. Additional options for treatment in these patients may include intravenous immune globulin, plasmapheresis, or anti-B cell targeted therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4297/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2642016\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Host defense against pathogenic (M. tuberculosis or TB) and nontuberculous (atypical, NTM) mycobacteria, as well as salmonella, depends heavily upon the functional integrity of interferon gamma",
"      <span class=\"nowrap\">",
"       (IFN-gamma)/IL-12",
"      </span>",
"      pathway. IFN-gamma is a principal factor in the elimination of both TB and NTM. Genetic defects in the IFN-gamma pathway result in Mendelian susceptibility to mycobacterial diseases (MSMD). Patients with defects in IFN-gamma receptor 1 (IFN-gamma-R1), IFN-gamma receptor 2 (IFN-gamma-R2), interleukin-12 receptor beta1 (IL-12Rbeta1), IL-12 p40, and signal transducer and activator of transcription 1 (STAT1) have been identified. Defects in nuclear factor kappa B essential modulator (NEMO) and gp91phox can cause X-linked MSMD. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Biology of the interferon gamma pathway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autosomal recessive",
"      <strong>",
"       complete",
"      </strong>",
"      IFN-gamma-R1 or IFN-gamma-R2 deficient patients tend to develop severe disseminated mycobacterial disease in infancy or early childhood, requiring continuous antimycobacterial therapy. Autosomal dominant IFN-gamma-R1 deficiency usually present later in childhood or in adolescence with severe localized or disseminated BCG or NTM infections, histoplasmosis, or salmonellosis. Almost all patients with autosomal dominant IFN-gamma-R deficiency develop multifocal NTM osteomyelitis, the hallmark for this genotype. The clinical phenotype of partial defects in IFN-gamma-R1 or IFN-gamma-R2 is usually milder than that of patients with complete defects. Affected patients with partial defects can have normal granuloma formation and tend to present later in life with rather limited disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Interferon gamma receptor deficiencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IL-12Rbeta1 deficiency may present with disseminated tuberculosis or nontuberculous mycobacterial and Salmonella infections in the setting of IL-12 unresponsiveness. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'IL-12 receptor beta1 deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IL-12p40 deficiency has a milder clinical phenotype than complete IFN-gamma-R1 or IFN-gamma-R2 deficiencies, since residual IL-12 independent IFN-gamma secretion pathways persist, as reflected by patients' capacity to form organized granulomata. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'IL-12p40 deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two types of STAT1 deficiency have been reported. The clinical and cellular phenotype of autosomal dominant defect is similar to those of patients with recessive IFN-gamma-R deficiency. In contrast, autosomal recessive complete STAT1 deficiency is a severe form of innate immunodeficiency that leads to increased susceptibility to both mycobacterial and viral infections. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'STAT1 deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two types of IRF8 deficiency have been reported. The autosomal recessive form results in a severe immunodeficiency with complete lack of monocytes and dendritic cells. In contrast, the autosomal dominant form is milder, with selective depletion of circulating dendritic cells. (See",
"      <a class=\"local\" href=\"#H1016484\">",
"       'IRF8 deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GATA2 deficiency leads to the syndrome of monocytopenia and mycobacterial disease (MonoMAC), which is characterized by late childhood or adult onset of disseminated nontuberculous mycobacterial disease or disseminated fungal disease. (See",
"      <a class=\"local\" href=\"#H3663155\">",
"       'GATA2 deficiency (MonoMAC syndrome)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis is established by flow cytometric evaluation of cell surface receptor expression on monocytes and lymphocytes as well as examining signaling either by intracellular staining (lack of STAT1 phosphorylation in response to IFN-gamma or STAT4 phosphorylation in response to IL-12) or Western blot. Detection of the mutation at the molecular level confirms the diagnosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Interferon gamma receptor deficiencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis in patients with disseminated NTM infections includes HIV infection, ectodermal dysplasia with immunodeficiency (EDID) due to mutations in NF-kappa B essential modifier (NEMO), GATA2 deficiency, chronic granulomatous disease (CGD), anti-interferon-gamma antibodies, or rarely other T cell immunodeficiencies, such as severe combined immunodeficiency (SCID). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Interferon gamma receptor deficiencies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H673461\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aggressive treatment with antimycobacterial antibiotics remains as the single accepted method for the management of patients with these disorders. Cytokine replacement therapy with IFN-gamma is an additional treatment option with most defects. However, it has limited efficacy among patients with autosomal recessive complete defects of IFN-gamma-R1 and IFN-gamma-R2, since unexpressed receptors lead to a failure to respond to IFN-gamma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Interferon gamma receptor deficiencies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/1\">",
"      Al-Muhsen S, Casanova JL. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 2008; 122:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/2\">",
"      Stenger S, Modlin RL. T cell mediated immunity to Mycobacterium tuberculosis. Curr Opin Microbiol 1999; 2:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/3\">",
"      Holland SM, Dorman SE, Kwon A, et al. Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency. J Infect Dis 1998; 178:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/4\">",
"      Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/5\">",
"      Lamhamedi S, Jouanguy E, Altare F, et al. Interferon-gamma receptor deficiency: relationship between genotype, environment, and phenotype (Review). Int J Mol Med 1998; 1:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/6\">",
"      Altare F, Jouanguy E, Lamhamedi-Cherradi S, et al. A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child. Am J Hum Genet 1998; 62:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/7\">",
"      Altare F, Jouanguy E, Lamhamedi S, et al. Mendelian susceptibility to mycobacterial infection in man. Curr Opin Immunol 1998; 10:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/8\">",
"      Roesler J, Kofink B, Wendisch J, et al. Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options. Exp Hematol 1999; 27:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/9\">",
"      Dorman SE, Uzel G, Roesler J, et al. Viral infections in interferon-gamma receptor deficiency. J Pediatr 1999; 135:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/10\">",
"      Flesch IE, Hess JH, Huang S, et al. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med 1995; 181:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/11\">",
"      Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/12\">",
"      Shuai K, Schindler C, Prezioso VR, Darnell JE Jr. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 1992; 258:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/13\">",
"      Shuai K, Stark GR, Kerr IM, Darnell JE Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993; 261:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/14\">",
"      Jouanguy E, Dupuis S, Pallier A, et al. In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma. J Clin Invest 2000; 105:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/15\">",
"      Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J Clin Invest 1998; 101:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/16\">",
"      Dorman SE, Picard C, Lammas D, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004; 364:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/17\">",
"      Casanova JL, Ochs H. Interferon-gamma receptor deficiency: An expanding clinical phenotype? J Pediatr 1999; 135:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/18\">",
"      Fleisher TA, Dorman SE, Anderson JA, et al. Detection of intracellular phosphorylated STAT-1 by flow cytometry. Clin Immunol 1999; 90:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/19\">",
"      Holland SM. Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection. Microbes Infect 2000; 2:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/20\">",
"      Holland SM. Immunotherapy of mycobacterial infections. Semin Respir Infect 2001; 16:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/21\">",
"      Roesler J, Horwitz ME, Picard C, et al. Hematopoietic stem cell transplantation for complete IFN-gamma receptor 1 deficiency: a multi-institutional survey. J Pediatr 2004; 145:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/22\">",
"      Moilanen P, Korppi M, Hovi L, et al. Successful hematopoietic stem cell transplantation from an unrelated donor in a child with interferon gamma receptor deficiency. Pediatr Infect Dis J 2009; 28:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/23\">",
"      Chantrain CF, Bruwier A, Brichard B, et al. Successful hematopoietic stem cell transplantation in a child with active disseminated Mycobacterium fortuitum infection and interferon-gamma receptor 1 deficiency. Bone Marrow Transplant 2006; 38:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/24\">",
"      Jouanguy E, Lamhamedi-Cherradi S, Lammas D, et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 1999; 21:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/25\">",
"      Foote S. Mediating immunity to mycobacteria. Nat Genet 1999; 21:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/26\">",
"      Levin M, Newport M. Understanding the genetic basis of susceptibility to mycobacterial infection. Proc Assoc Am Physicians 1999; 111:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/27\">",
"      Ottenhoff TH, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. Immunol Today 1998; 19:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/28\">",
"      Jouanguy E, Lamhamedi-Cherradi S, Altare F, et al. Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Gu&eacute;rin infection and a sibling with clinical tuberculosis. J Clin Invest 1997; 100:2658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/29\">",
"      D&ouml;ffinger R, Jouanguy E, Dupuis S, et al. Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Gu&eacute;rin and Mycobacterium abscessus infection. J Infect Dis 2000; 181:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/30\">",
"      de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998; 280:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/31\">",
"      Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998; 280:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/32\">",
"      Caragol I, Raspall M, Fieschi C, et al. Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor beta1 deficiency. Clin Infect Dis 2003; 37:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/33\">",
"      Staretz-Haham O, Melamed R, Lifshitz M, et al. Interleukin-12 receptor beta1 deficiency presenting as recurrent Salmonella infection. Clin Infect Dis 2003; 37:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/34\">",
"      Lichtenauer-Kaligis EG, de Boer T, Verreck FA, et al. Severe Mycobacterium bovis BCG infections in a large series of novel IL-12 receptor beta1 deficient patients and evidence for the existence of partial IL-12 receptor beta1 deficiency. Eur J Immunol 2003; 33:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/35\">",
"      Fieschi C, Dupuis S, Catherinot E, et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J Exp Med 2003; 197:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/36\">",
"      Haerynck F, Holland SM, Rosenzweig SD, et al. Disseminated Mycobacterium avium infection in a patient with a novel mutation in the interleukin-12 receptor-beta1 chain. J Pediatr 2008; 153:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/37\">",
"      Gruenberg DA, A&ntilde;over-Sombke S, Gern JE, et al. Atypical presentation of IL-12 receptor beta1 deficiency with pneumococcal sepsis and disseminated nontuberculous mycobacterial infection in a 19-month-old girl born to nonconsanguineous US residents. J Allergy Clin Immunol 2010; 125:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/38\">",
"      de Beaucoudrey L, Samarina A, Bustamante J, et al. Revisiting human IL-12R&beta;1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 2010; 89:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/39\">",
"      Altare F, Lammas D, Revy P, et al. Inherited interleukin 12 deficiency in a child with bacille Calmette-Gu&eacute;rin and Salmonella enteritidis disseminated infection. J Clin Invest 1998; 102:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/40\">",
"      Picard C, Fieschi C, Altare F, et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet 2002; 70:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/41\">",
"      Dupuis S, Dargemont C, Fieschi C, et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001; 293:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/42\">",
"      Chapgier A, Boisson-Dupuis S, Jouanguy E, et al. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet 2006; 2:e131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/43\">",
"      Dupuis S, Jouanguy E, Al-Hajjar S, et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 2003; 33:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/44\">",
"      Chapgier A, Wynn RF, Jouanguy E, et al. Human complete Stat-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo. J Immunol 2006; 176:5078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/45\">",
"      Chapgier A, Kong XF, Boisson-Dupuis S, et al. A partial form of recessive STAT1 deficiency in humans. J Clin Invest 2009; 119:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/46\">",
"      Averbuch D, Chapgier A, Boisson-Dupuis S, et al. The clinical spectrum of patients with deficiency of Signal Transducer and Activator of Transcription-1. Pediatr Infect Dis J 2011; 30:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/47\">",
"      Weisz A, Marx P, Sharf R, et al. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J Biol Chem 1992; 267:25589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/48\">",
"      Chiquet BT, Lidral AC, Stal S, et al. CRISPLD2: a novel NSCLP candidate gene. Hum Mol Genet 2007; 16:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/49\">",
"      Marquis JF, LaCourse R, Ryan L, et al. Disseminated and rapidly fatal tuberculosis in mice bearing a defective allele at IFN regulatory factor 8. J Immunol 2009; 182:3008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/50\">",
"      Hambleton S, Salem S, Bustamante J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011; 365:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/51\">",
"      Vinh DC, Patel SY, Uzel G, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010; 115:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/52\">",
"      Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011; 118:2653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/53\">",
"      Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 2011; 118:2656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/54\">",
"      Cuellar-Rodriguez J, Gea-Banacloche J, Freeman AF, et al. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood 2011; 118:3715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/55\">",
"      Bustamante J, Arias AA, Vogt G, et al. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol 2011; 12:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/56\">",
"      Patel SY, Ding L, Brown MR, et al. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol 2005; 175:4769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/57\">",
"      Browne SK, Holland SM. Immunodeficiency secondary to anticytokine autoantibodies. Curr Opin Allergy Clin Immunol 2010; 10:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/58\">",
"      Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 2012; 367:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/59\">",
"      D&ouml;ffinger R, Helbert MR, Barcenas-Morales G, et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis 2004; 38:e10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4297/abstract/60\">",
"      H&ouml;flich C, Sabat R, Rosseau S, et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 2004; 103:673.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3958 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4297=[""].join("\n");
var outline_f4_12_4297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2642016\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Biology of the interferon gamma pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTERFERON GAMMA RECEPTOR DEFICIENCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Autosomal recessive complete IFN-gamma receptor deficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autosomal dominant IFN-gamma-R1 deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Autosomal recessive partial IFN-gamma receptor deficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IL-12 RECEPTOR BETA1 DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IL-12P40 DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      STAT1 DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1016484\">",
"      IRF8 DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3663155\">",
"      GATA2 DEFICIENCY (MonoMAC SYNDROME)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11422897\">",
"      OTHER DEFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H673461\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2642016\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3958\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3958|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/59/6070\" title=\"figure 1\">",
"      Critical pathways in controlling mycobacterial infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=related_link\">",
"      Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=related_link\">",
"      Chronic granulomatous disease: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=related_link\">",
"      Chronic mucocutaneous candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=related_link\">",
"      Flow cytometry for the diagnosis of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30009?source=related_link\">",
"      Idiopathic CD4+ lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25288?source=related_link\">",
"      Pathogenesis of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_12_4298="Treatment of latent tuberculosis infection in HIV-infected patients";
var content_f4_12_4298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of latent tuberculosis infection in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/12/4298/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/12/4298/contributors\">",
"     Dick Menzies, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/12/4298/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/12/4298/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/12/4298/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/12/4298/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/12/4298/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H107991584\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The profound impact of HIV infection on the epidemiology, clinical manifestations and outcome of tuberculosis (TB) was noted soon after the discovery of HIV as the causative agent of AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The intersection of these two epidemics has led to a major upsurge in TB cases, particularly in resource-limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The World Health Organization (WHO) estimates that 13 percent of deaths in AIDS patients worldwide are related to TB [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/6\">",
"     6",
"    </a>",
"    ]. The negative impact of HIV on TB disease has been particularly notable in sub-Saharan Africa, where the incidence of TB has increased more than fivefold [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/4,5,7\">",
"     4,5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will address the prevention of active TB disease through treatment of latent tuberculosis (LTBI) in the HIV-infected patient. The diagnosis of LTBI in the HIV-infected patient and treatment of active TB disease are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/46/12009?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8400290\">",
"    <span class=\"h1\">",
"     GENERAL CONCEPTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H670905\">",
"    <span class=\"h2\">",
"     What is latent TB infection?",
"    </span>",
"    &nbsp;&mdash;&nbsp;TB infection is caused by inhalation of viable bacilli, which usually persist in an inactive state known as latent TB infection (LTBI) or sometimes progress rapidly to active TB disease. Persons with LTBI are asymptomatic and not infectious. However, these latent TB bacilli remain viable and may &ldquo;reactivate&rdquo; years later and cause active symptomatic, and often transmissible, TB disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H670912\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Terms used in the literature, which refer to management of LTBI, include &ldquo;treatment of LTBI,&rdquo; &ldquo;TB chemoprophylaxis,&rdquo; or &ldquo;TB preventive therapy.&rdquo; In this topic, we will use &ldquo;treatment of LTBI.&rdquo;",
"   </p>",
"   <p>",
"    The diagnosis of LTBI in HIV-infected patients is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/46/12009?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H670608\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR PROGRESSION TO ACTIVE TB DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H670919\">",
"    <span class=\"h2\">",
"     Clinical and demographic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical or demographic characteristics, known to increase the risk of tuberculosis (TB) infection or reactivation in HIV-uninfected persons, are also likely to increase the risk of active TB in HIV-infected individuals. These risk factors include an abnormal chest x-ray (eg, fibrotic lesion) or contact with an active TB case. Other risk factors also apply, including a positive skin test for latent TB infection (LTBI) and origin from a country with high TB incidence rates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H670926\">",
"    <span class=\"h2\">",
"     HIV-related parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition, among HIV-infected patients, the following risk factors are associated with development of active TB disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low CD4 cell counts (eg, &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"     </li>",
"     <li>",
"      Detectable HIV RNA",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, observational and clinical trial data suggest that antiretroviral therapy (ART) confers an independent reduction in risk of developing active TB disease among those with latent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/9,10,13,14\">",
"     9,10,13,14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6037138\">",
"     'Initiation of antiretroviral therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8400317\">",
"    <span class=\"h1\">",
"     RATIONALE TO TREAT LATENT TB",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H670933\">",
"    <span class=\"h2\">",
"     Treatment of latent TB reduces active disease and transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among HIV-infected patients in Africa with evidence of latent TB (LTBI), the risk of developing active TB disease without antituberculous treatment ranges from 5 to 10 percent each year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/6,15,16\">",
"     6,15,16",
"    </a>",
"    ]. However, effective treatment regimens for LTBI have been shown to reduce the risk of active disease, thus preventing TB-related morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/7,17,18\">",
"     7,17,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6036760\">",
"     'Clinical trials of latent TB treatment in HIV-infected patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment of LTBI also has other public health benefits, including the reduction of TB transmission among persons living in areas of high and low TB incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/9,15,19\">",
"     9,15,19",
"    </a>",
"    ]. Mathematical models have predicted that provision of LTBI therapy to at least one-half of those with HIV and LTBI would be cost effective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/20\">",
"     20",
"    </a>",
"    ] and would result in a substantial reduction in TB disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/19\">",
"     19",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    For these reasons, treatment of LTBI in HIV-infected persons has been strongly recommended for many years by expert panels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, despite consistent and clear recommendations from these authoritative agencies, including the World Health Organization (WHO) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/6,23\">",
"     6,23",
"    </a>",
"    ], it is estimated that only 1.3 percent of all HIV-infected patients with LTBI worldwide receive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/5\">",
"     5",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12660510\">",
"    <span class=\"h2\">",
"     Interactions between HIV and tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians need to be aware of the important impact HIV status has on LTBI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following primary TB infection, HIV-infected patients are at higher risk of progressing to active TB disease compared with HIV-seronegative individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. In addition, the interval from exposure to disease can be less than two months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compared with HIV-uninfected individuals, HIV-infected patients with LTBI are 30 to 100 times more likely to reactivate with TB disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/27-30\">",
"       27-30",
"      </a>",
"      ], particularly those with advanced immunosuppression [",
"      <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interactions between HIV and TB are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\", section on 'Interactions between HIV and tuberculosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107991598\">",
"    <span class=\"h1\">",
"     SCREENING FOR LATENT TB INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H670948\">",
"    <span class=\"h2\">",
"     Resource-rich settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;All HIV-infected patients living in resource-rich settings should be screened for latent tuberculosis infection (LTBI) as soon as their HIV infection has been identified. Those with positive tests for LTBI should be offered treatment. The sensitivity and specificity of the diagnostic assays used for the evaluation of possible LTBI are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/46/12009?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H670955\">",
"    <span class=\"h2\">",
"     Resource-limited settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) suggests that LTBI testing is not required in resource-limited settings if testing is not available due to constrained resources [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/6\">",
"     6",
"    </a>",
"    ]. However, clinicians should be aware that the benefits of LTBI treatment have only been shown among those with evidence of LTBI, as discussed below. Thus, when feasible, testing for LTBI is preferable to no testing. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6036760\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS OF LATENT TB TREATMENT IN HIV-INFECTED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both HIV-infected and uninfected individuals, the main agents that have been studied for LTBI include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    , the rifamycins (both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/14,31\">",
"     14,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1860468\">",
"    <span class=\"h2\">",
"     General background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple trials, most conducted in resource-limited settings, have evaluated the efficacy, safety, and feasibility of short and long-term prophylactic therapy for the prevention of TB in the HIV-infected host. Both monotherapy and combination therapy regimens have been assessed in an effort to identify the most efficacious regimen with the shortest duration and overall favorable toxicity profile. The number of clinical events (eg, active TB disease) observed within each trial is also influenced by the geographic areas where the studies were performed; for example, the number of HIV-infected patients developing active TB is much higher in resource-limited than in resource-rich settings, reflecting the differences in transmission risk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/9,11,14,16,32\">",
"     9,11,14,16,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical data discussed below include a 2010 Cochrane meta-analysis and clinical trials that were performed after this analysis was published.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1860475\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2010, a meta-analysis was performed of 12 controlled trials conducted among 8578 HIV-infected patients who were randomly assigned to preventive TB therapy or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/11,15,16,32-42\">",
"     11,15,16,32-42",
"    </a>",
"    ]. The trials were conducted in resource-limited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/10,11,14,16,32,36-39,43\">",
"     10,11,14,16,32,36-39,43",
"    </a>",
"    ] and resource-rich settings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/33,35,40,41\">",
"     33,35,40,41",
"    </a>",
"    ]. The study participants could be either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    positive or negative; anergic patients were considered negative in the analysis. The following regimens were included in the meta-analysis:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    alone, dual therapy with isoniazid plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    or rifampin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , and triple therapy with isoniazid, rifampin, plus pyrazinamide [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/15\">",
"     15",
"    </a>",
"    ]. The following observations were illustrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with placebo, treatment for LTBI reduced the risk of active TB by 32 percent.",
"     </li>",
"     <li>",
"      All drug regimens, regardless of type, frequency, or duration of treatment, reduced the incidence of active TB compared with placebo.",
"     </li>",
"     <li>",
"      The benefit of therapy was restricted to those with a documented positive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      ; among patients who were tuberculin skin test positive, therapy reduced the risk of active TB by 62 percent (four trials; 2378 participants; RR 0.38, 95% CI 0.25-0.57). In contrast, therapy did not reduce the risk of active TB, compared with placebo in patients with a negative tuberculin skin test (seven trials; 2822 participants; RR 0.89, 95% CI 0.64-1.24).",
"     </li>",
"     <li>",
"      The treatment of LTBI was not associated with a reduction in overall mortality; however, most patients in this analysis were not taking antiretroviral therapy.",
"     </li>",
"     <li>",
"      Compared with placebo, treatment for LTBI was associated with an increased risk of adverse events. This risk was higher for combination regimens than for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      monotherapy.",
"     </li>",
"     <li>",
"      Limited information was available on the duration of protection against active TB disease after treatment for latent infection was discontinued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two subsequent trials from Botswana and South Africa reinforce some of the general concepts already highlighted, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1860610\">",
"    <span class=\"h2\">",
"     Botswana",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical trial randomly assigned 1995 HIV-infected patients, with or without documented LTBI, to six months of daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (300 mg) followed by extended isoniazid or extended placebo for 30 months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/10\">",
"     10",
"    </a>",
"    ]. Antiretroviral therapy was provided for participants with a CD4 count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    The trial demonstrated the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of active TB was significantly lower in the extended",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      group compared with the extended placebo group (20 versus 34 cases; hazard ratio 0.57, 95% CI 0.33-0.99).",
"     </li>",
"     <li>",
"      The incidence of TB among those individuals receiving extended placebo increased significantly approximately 200 days after completion of the first six months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The clinical benefit of extended",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      was only seen in those with a positive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      By study completion, 946 (47 percent) of the participants had initiated ART and were taking therapy for approximately one year. TB incidence was reduced by 50 percent among those receiving ART compared with those who remained off ART.",
"     </li>",
"     <li>",
"      Adverse events were comparable between arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1860510\">",
"    <span class=\"h2\">",
"     South Africa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from an earlier trial in Zambia raised the question as to whether long-term preventive therapy is needed in TB endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/11\">",
"     11",
"    </a>",
"    ]. On the other hand, general concerns have been raised about long-term treatment because of the burden on patients and the potential risk of acquired drug resistance.",
"   </p>",
"   <p>",
"    In a clinical trial conducted in South Africa, 1148 HIV-infected patients with a median CD4 cell count of 484",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and a positive TST were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    (900 mg) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (900 mg) weekly for 12 weeks,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (600 mg) plus isoniazid (900 mg) twice weekly for 12 weeks, isoniazid (300 mg) daily for up to six years (ie, &ldquo;continuous isoniazid&rdquo;), or isoniazid (300 mg) daily for six months (control group) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/14\">",
"     14",
"    </a>",
"    ]. All doses of drugs within the combination therapy arms were given through direct observation while doses in the isoniazid arms were self-administered. None of the patients were taking ART. The trial demonstrated the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence rates of active TB and death were similar in all arms",
"     </li>",
"     <li>",
"      Rates of hepatotoxicity were significantly higher in the continuous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      arm than all other arms.",
"     </li>",
"     <li>",
"      Many patients in the continuous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      arm self-discontinued therapy; those who continued to adhere to medications in the continuous isoniazid arm had a decreased rate of TB and death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No selection of drug resistance was suggested by the trial results, although the overall number of culture-confirmed cases was small (ie 62 cases).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2403880\">",
"    <span class=\"h2\">",
"     North America",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a clinical trial of 7731 patients with LTBI, once-weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    , given under direct observation for 12 weeks, was found to be equivalent in efficacy to isoniazid monotherapy self-administered daily for nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/44\">",
"     44",
"    </a>",
"    ]. Only 3 percent of the study population (n = 161) were HIV-infected, and randomization was not stratified by HIV status, so there was some imbalance in the number of HIV infected patients allocated to each treatment: 87 patients were assigned to the dual therapy arm compared with 74 patients in the isoniazid arm.",
"   </p>",
"   <p>",
"    In 2011, the Centers for Disease Control suggested that weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    given under direct observation for 12 weeks is an alternative therapeutic option for the treatment of LTBI among HIV-infected patients who do not require HIV therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This trial is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link&amp;anchor=H26951774#H26951774\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\", section on 'Isoniazid and rifapentine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1861123\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of LTBI is effective in preventing active TB disease among HIV-infected patients. Effective regimens include:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    alone, dual therapy with isoniazid plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    or rifampin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , and triple therapy with isoniazid, rifampin, plus pyrazinamide [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/15\">",
"     15",
"    </a>",
"    ]. Rifampin monotherapy has not been studied in this patient population. The clinical benefit of treatment is evident among those with documented LTBI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]. Isoniazid monotherapy is the generally preferred agent for LTBI because of its favorable toxicity profile and overall improved treatment completion rates, compared with combination therapy, as discussed below.",
"   </p>",
"   <p>",
"    Based on the limited data above, an additional option for otherwise healthy HIV-infected patients with LTBI who are not taking ART includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    given as directly observed doses together once weekly for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/44,46\">",
"     44,46",
"    </a>",
"    ]. This is an attractive option for patients who may not be able to adhere to nine months of daily therapy with isoniazid. However, HIV-infected patients on ART should not be treated with isoniazid plus rifapentine since there are few data on drug-drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12660997\">",
"    <span class=\"h1\">",
"     DRUG TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse events and drug discontinuation rates are generally lower among patients taking monotherapy compared with combination therapy and among those taking short-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    compared with long-term isoniazid [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/10,11,15\">",
"     10,11,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12661024\">",
"    <span class=\"h2\">",
"     Isoniazid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     Isoniazid",
"    </a>",
"    is effective in preventing TB disease among HIV-uninfected and HIV-infected patients with latent TB infection (LTBI) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/10,14,15,43\">",
"     10,14,15,43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6036760\">",
"     'Clinical trials of latent TB treatment in HIV-infected patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The major toxicities associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    include peripheral neuropathy and hepatotoxicity. HIV-infected patients who receive isoniazid should also receive supplemental vitamin B6 to prevent peripheral neuropathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral neuropathy can also be associated with the HIV nucleoside analog",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      , which is no longer recommended for HIV therapy, including in resource-limited settings. Patients who are initiating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      should not take concomitant stavudine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10794?source=see_link&amp;anchor=H9#H9\">",
"       \"Adverse effects of antiretroviral therapy in developing countries\", section on 'Peripheral neuropathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-induced liver injury has been associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/47\">",
"       47",
"      </a>",
"      ] as well as certain antiretroviral medications for HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/48\">",
"       48",
"      </a>",
"      ]. Patients should also be educated regarding the signs and symptoms of hepatitis. (See",
"      <a class=\"local\" href=\"#H12662001\">",
"       'Patient monitoring'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12661031\">",
"    <span class=\"h2\">",
"     Rifamycins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    have been evaluated for prevention of TB in HIV-infected and uninfected patients, usually given in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/14,15,49,50\">",
"     14,15,49,50",
"    </a>",
"    ]. Rifapentine has similar anti-TB potency as rifampin, but with a half-life that is five times longer, allowing this to be given once weekly.",
"   </p>",
"   <p>",
"    In HIV-uninfected patients, monotherapy with rifamycins is associated with a lower risk of hepatotoxicity than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/15,49-52\">",
"     15,49-52",
"    </a>",
"    ]. Other uncommon adverse effects include gastrointestinal (nausea, vomiting, diarrhea), central nervous system (headache, fever), dermatologic (rash, itching, flushing) and hematologic (thrombocytopenia and acute hemolytic anemia) reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/49-51,53\">",
"     49-51,53",
"    </a>",
"    ]. These adverse events occur in 1 to 2 percent of HIV-uninfected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/51,54,55\">",
"     51,54,55",
"    </a>",
"    ]. However, clinical trials of LTBI treatment in HIV-infected patients have used rifamycins in combination with other agents (eg, isoniazid) so the individual toxicity profile of rifamycins in this patient population is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=see_link&amp;anchor=H9#H9\">",
"     \"Rifampin and other rifamycins\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major concern regarding the use of rifamycins in HIV-infected patients is related to potential drug-drug interactions with antiretroviral medications. Rifamycins induce hepatic CYP3A4 enzymes that can accelerate metabolism of HIV protease inhibitors (PIs) and some non-nucleoside reverse transcriptase inhibitors (NNRTIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    causes much fewer drug interactions, there are no data on its use as monotherapy for LTBI in HIV-infected patients. In addition, there has been greater toxicity associated with rifabutin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=see_link&amp;anchor=H9#H9\">",
"     \"Rifampin and other rifamycins\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12661038\">",
"    <span class=\"h2\">",
"     Combination regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high incidence of drug-induced liver injury was identified in patients treated with a two-month regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    for LTBI, although the risk appeared to be lower among HIV-infected patients compared with HIV-seronegative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/59\">",
"     59",
"    </a>",
"    ]. However, regardless of HIV serostatus, the Centers for Disease Control and Prevention (CDC), American Thoracic Society (ATS), and Infectious Diseases Society of America (IDSA) recommend against using rifampin plus pyrazinamide for latent infections in any patient unless the benefit clearly outweighs the risk, or if other regimens cannot be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1860402\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to review general treatment concepts that have emerged in studies of HIV-uninfected patients with latent tuberculosis infection (LTBI) and how these concepts apply to HIV-infected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3356880\">",
"    <span class=\"h2\">",
"     General concepts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal duration of INH therapy involves a trade-off between better efficacy, but reduced adherence with longer therapy. Factors that need to be considered in determining the duration of treatment include medication adherence and drug toxicity. The duration of treatment of LTBI varies by geographic location; the difference is largely related to the likelihood of recurrent TB exposure and reinfection. (See",
"    <a class=\"local\" href=\"#H6037122\">",
"     'Management strategies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     Isoniazid",
"    </a>",
"    prophylaxis been studied in varying durations of 3, 6, 9, and 12 months among HIV-uninfected patients for the prevention of active TB disease. In general, a longer duration of prophylaxis has been associated with greater reduction in risk of TB disease compared with shorter courses of therapy.",
"   </p>",
"   <p>",
"    The potential benefits of long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    are likely to be seen only in very high transmission settings, and even in these settings must be weighed against the greater toxicity, cost, decreased completion rates, and burden on patients compared to shorter regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/14,60\">",
"     14,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1454119\">",
"    <span class=\"h3\">",
"     Efficacy versus effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The &ldquo;efficacy&rdquo; of an intervention is determined by those patients who take the medication as recommended, while &ldquo;effectiveness&rdquo; takes into account the patient&rsquo;s ability to comply with a particular intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/61\">",
"     61",
"    </a>",
"    ]. This is an important concept in treatment of LTBI, since longer courses of therapy have been associated with lower completion rates in studies of both HIV-infected and HIV-uninfected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/10,14,15,61\">",
"     10,14,15,61",
"    </a>",
"    ]. For example, among HIV-seronegative patients, 12 months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    is associated with greater efficacy than six months of isoniazid [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/61\">",
"     61",
"    </a>",
"    ]. However, lower rates of adherence and treatment completion that are associated with longer courses of prophylaxis result in similar overall effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1454133\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some analyses in HIV-seronegative patients have suggested that a shorter duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    may decrease the risk of hepatotoxicity, which may improve the risk-benefit ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1454126\">",
"    <span class=\"h3\">",
"     Data extrapolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of these considerations have led to subgroup analyses in HIV-seronegative patients that compare efficacy, effectiveness, and toxicity; these analyses have suggested that a duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    therapy of nine months may provide the optimal balance of benefit with risk through data extrapolation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/21,61\">",
"     21,61",
"    </a>",
"    ]. Thus, nine months of isoniazid therapy is currently recommended by multiple expert guidelines for the prevention of active TB disease in HIV-seronegative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/7,21,61\">",
"     7,21,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\", section on 'Selecting a regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1861617\">",
"    <span class=\"h2\">",
"     Comparisons of duration of chemoprophylaxis among HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among HIV-infected patients with LTBI, clinical trials have evaluated courses of therapy ranging from six months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    to lifelong interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/6,10,14,31,43,60-62\">",
"     6,10,14,31,43,60-62",
"    </a>",
"    ]. Similar observations have been made regarding isoniazid, as noted in HIV-uninfected patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Longer courses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      monotherapy are associated with greater efficacy in the prevention of active TB disease compared with shorter courses of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/10,14\">",
"       10,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The effectiveness of treatment is reduced by medication nonadherence [",
"      <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/14\">",
"       14",
"      </a>",
"      ]. This is the most important cause of failure to prevent active TB in persons with known LTBI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of moderate or severe elevations of aminotransferases is greater with longer courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    compared with shorter courses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/14\">",
"     14",
"    </a>",
"    ], although the risk of symptomatic hepatitis may be comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/10\">",
"     10",
"    </a>",
"    ]. Conflicting results from various trials may be related to the frequency and methods of patient monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6037122\">",
"    <span class=\"h1\">",
"     MANAGEMENT STRATEGIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1454273\">",
"    <span class=\"h2\">",
"     Indications for TB preventive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All HIV-infected patients with evidence of latent tuberculosis infection (LTBI) should receive therapy for the prevention of active tuberculosis (TB) disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/15,63\">",
"     15,63",
"    </a>",
"    ]. There is no demonstrable benefit of administering treatment among patients who have negative tests for LTBI or who are anergic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/10,15\">",
"     10,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in view of the increased likelihood of infection and increased risk of disease, treatment is also recommended for HIV-infected patients with recent contact with a person with active TB disease or in those with a history of untreated or inadequately treated healed TB (eg, fibrotic disease on chest x-ray), regardless of test results for LTBI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H670608\">",
"     'Risk factors for progression to active TB disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In 2011, the World Health Organization (WHO) recommended testing for LTBI, prior to initiation of chemoprophylaxis, but also suggested this should not be an absolute requirement among HIV-infected patients living in areas of high TB incidence. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/46/12009?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6037130\">",
"    <span class=\"h2\">",
"     Treatment regimens and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of treatment of LTBI varies by geographic location; the difference is largely related to the likelihood of recurrent TB exposure and re-infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6038924\">",
"    <span class=\"h3\">",
"     Resource-rich settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various expert panels on guideline committees recommend nine months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    for the HIV-infected patient living in resource-rich settings based on inference from clinical trials in HIV-seronegative patients and on subgroup analyses of data from trials using treatment interventions of different durations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/7,21,22,61\">",
"     7,21,22,61",
"    </a>",
"    ]. However, the optimal duration of therapy remains unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authoritative agencies recommend six months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    or four months",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    as acceptable alternatives [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, there are no data on the use of rifampin as monotherapy for prevention of active TB disease in the HIV-infected patient. Furthermore, drug-drug interactions must be scrutinized before rifampin is combined with certain antiretroviral medications, such as protease inhibitors or nonnucleoside reverse transcriptase inhibitors (NNRTIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/57,63\">",
"     57,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6038931\">",
"    <span class=\"h3\">",
"     Resource-limited settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In geographic locations with very high rates of TB incidence and transmission, the benefit of therapy wanes after treatment discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/14\">",
"     14",
"    </a>",
"    ]. In these settings, the WHO guidelines recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    monotherapy for a minimum of six months in HIV-infected patients with consideration of up to 36 months of treatment, based on clinical trial data suggesting benefit of longer therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/10,14\">",
"     10,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, extended",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    therapy (ie, beyond 12 months) is associated with increased costs and burden for patients, and can be associated with increased toxicity and non-completion of treatment, which compromises treatment effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/14\">",
"     14",
"    </a>",
"    ]. In large-scale programs in resource-limited settings, shorter courses of therapy may be more cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    WHO has not recommended any alternate regimen other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    monotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6037138\">",
"    <span class=\"h2\">",
"     Initiation of antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) recommends ART in all HIV-infected patients with active TB, irrespective of CD4 cell count. The expert panel from the Department of Health and Human Services (DHHS) recommends &ldquo;integrated ART&rdquo; (eg, within 2 to 12 weeks after initiating anti-TB therapy) rather than &ldquo;sequential ART&rdquo; for",
"    <span class=\"nowrap\">",
"     HIV/TB",
"    </span>",
"    coinfected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/64\">",
"     64",
"    </a>",
"    ]. Prior studies suggested a benefit for earlier initiation of ART on the incidence of tuberculosis among patients living in TB-endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/9,10,65-67\">",
"     9,10,65-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H26#H26\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'Treatment recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265621\">",
"    <span class=\"h2\">",
"     Assessment for TB disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiation of treatment for LTBI, all patients must be scrutinized for active TB infection to avoid monotherapy and the risk of TB drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/46/12009?source=see_link&amp;anchor=H15333916#H15333916\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-infected patients\", section on 'Evaluation for active TB disease prior to treatment of latent infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians should be aware that HIV-infected patients with a CD4 cell count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    are at increased risk of active TB [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/68\">",
"     68",
"    </a>",
"    ]. Patients with advanced immunosuppression may present with atypical clinical manifestations including extrapulmonary TB disease, mediastinal lymphadenopathy, or with subclinical infection and a normal chest x-ray. The diagnosis of active TB disease is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H669971\">",
"    <span class=\"h2\">",
"     Baseline laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine baseline laboratory testing is not required prior to the initiation of treatment of LTBI. However, persons with a history of liver disease (eg, alcoholic, viral hepatitis) should have baseline testing of aminotransferases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/21\">",
"     21",
"    </a>",
"    ]. Some experts suggest withholding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    treatment in patients with symptomatic hepatitis with an alanine aminotransferase level (ALT) greater than three times the upper limit of normal and among those with an ALT greater than five times the upper limit of normal, regardless of the presence or absence of symptomatic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/21,47\">",
"     21,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12662001\">",
"    <span class=\"h2\">",
"     Patient monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient monitoring for symptoms suggestive of adverse drug-related events, or the development of active TB, should occur at least monthly. Regular patient-doctor interactions provide an opportunity to also reinforce the importance of drug adherence.",
"   </p>",
"   <p>",
"    The risk of drug-induced hepatotoxicity associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    increases with older age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/69\">",
"     69",
"    </a>",
"    ] and heavy alcohol use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/69\">",
"     69",
"    </a>",
"    ]. However there is no consistent evidence of increased toxicity of LTBI therapy in HIV-infected persons [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/33,70\">",
"     33,70",
"    </a>",
"    ]. In fact, in one trial of combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , the incidence of drug-induced liver injury was lower among the patients who were HIV-infected compared with those who were HIV-uninfected [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/33,70\">",
"     33,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no consensus on the need for, or benefits of, routine monitoring of aminotransferases in patients taking treatment for LTBI. However, all patients should be counseled on the symptoms and signs of drug-induced hepatitis (eg, right upper quadrant pain, jaundice, nausea, vomiting, loss of appetite, dark urine). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link&amp;anchor=H13#H13\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\", section on 'Hepatotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, if baseline aminotransferases are abnormal, routine monitoring is recommended, although the optimal frequency of monitoring is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/21\">",
"     21",
"    </a>",
"    ]. As noted above, baseline aminotransferases are obtained in patients with known or suspected liver disease. (See",
"    <a class=\"local\" href=\"#H669971\">",
"     'Baseline laboratory testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107991696\">",
"    <span class=\"h1\">",
"     TREATMENT OF SUSPECTED DRUG-RESISTANT LATENT TUBERCULOSIS INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention of active tuberculosis (TB) disease among HIV-infected patients with possible drug-resistant TB is covered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6038013\">",
"    <span class=\"h1\">",
"     TREATMENT DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the very high risk of active tuberculosis (TB) among all HIV-infected persons, and the substantial risk that active TB poses to the fetus, it is strongly recommended that HIV-infected women should undergo testing and treatment for latent tuberculosis (LTBI) regardless of whether they are pregnant or breast feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?4/12/4298/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=see_link&amp;anchor=H4#H4\">",
"     \"Tuberculosis in pregnancy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1862358\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persons with latent tuberculosis (LTBI) are asymptomatic and not infectious. However, these LTBI bacilli remain viable and may reactivate years later and cause active symptomatic, and often transmissible, tuberculosis (TB) disease. (See",
"      <a class=\"local\" href=\"#H8400290\">",
"       'General concepts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared with HIV-uninfected individuals, HIV-infected patients with LTBI are significantly more likely to reactivate with TB disease, particularly those with advanced immunosuppression. (See",
"      <a class=\"local\" href=\"#H12660510\">",
"       'Interactions between HIV and tuberculosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In both HIV-infected and uninfected individuals, the main agents that have studied for LTBI include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      , the rifamycins (both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"       rifapentine",
"      </a>",
"      ) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H12660997\">",
"       'Drug Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of LTBI is effective in preventing active TB disease among HIV-infected patients. Adverse events and drug discontinuation rates are generally lower among patients taking monotherapy compared with combination therapy and among those taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      for six to nine months compared with isoniazid for 36 months or longer. (See",
"      <a class=\"local\" href=\"#H6036760\">",
"       'Clinical trials of latent TB treatment in HIV-infected patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All HIV-infected patients with evidence of LTBI should receive therapy for the prevention of active TB disease (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). There is no demonstrable benefit of administering treatment among patients who have negative tests for LTBI or who are anergic. Treatment is also recommended for HIV-infected patients with recent contact with a person with active TB disease or in those with a history of untreated or inadequately treated healed TB (eg, fibrotic disease on chest x-ray), regardless of test results for LTBI. (See",
"      <a class=\"local\" href=\"#H1454273\">",
"       'Indications for TB preventive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       Isoniazid",
"      </a>",
"      is preferred for the treatment of LTBI in the HIV-infected patient because of its overall efficacy, safety, and cost. (See",
"      <a class=\"local\" href=\"#H6037130\">",
"       'Treatment regimens and duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal duration of therapy for LTBI is unknown. In resource-rich settings, most patients are treated with nine months of daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      (300 mg daily). In resource-limited settings, clinical trials have evaluated six months of isoniazid to lifelong therapy. The potential benefits of long-term isoniazid are likely to be seen only in high transmission settings and must be weighed against the greater toxicity, cost, and burden on patients compared to shorter regimens. (See",
"      <a class=\"local\" href=\"#H1860402\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies suggest a benefit for earlier initiation of antiretroviral therapy on the incidence of TB among patients living in endemic areas. Eligibility criteria for initiation of antiretroviral medications for HIV disease vary by geographic location. (See",
"      <a class=\"local\" href=\"#H6037138\">",
"       'Initiation of antiretroviral therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39018?source=see_link&amp;anchor=H12409069#H12409069\">",
"       \"The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings\", section on 'Effect of antiretroviral therapy on other comorbidities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prior to initiation of treatment for LTBI, all patients must be scrutinized for active TB infection to avoid monotherapy and the risk of TB drug resistance. (See",
"      <a class=\"local\" href=\"#H265621\">",
"       'Assessment for TB disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"       \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Routine baseline laboratory testing is not required prior to the initiation of treatment of LTBI. However, persons with a history of liver disease (eg, alcoholic, viral hepatitis) should have baseline testing of aminotransferases. (See",
"      <a class=\"local\" href=\"#H669971\">",
"       'Baseline laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no consensus on the need for routine monitoring of aminotransferases in patients taking treatment for LTBI. However, all patients should be counseled on the symptoms and signs of drug-induced hepatitis (eg, right upper quadrant pain, jaundice, nausea, vomiting, loss of appetite, dark urine). (See",
"      <a class=\"local\" href=\"#H12662001\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/1\">",
"      Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis 1992; 73:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/2\">",
"      Pitchenik AE, Burr J, Suarez M, et al. Human T-cell lymphotropic virus-III (HTLV-III) seropositivity and related disease among 71 consecutive patients in whom tuberculosis was diagnosed. A prospective study. Am Rev Respir Dis 1987; 135:875.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/tb/publications/global_report/2009/en/index.html (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     World Health Organization. Global Tuberculosis Control. Surveillance, Planning, Financing: 2010. World Health Organization, Geneva 2011 (WHO/HTM/TB/2010.362).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/5\">",
"      Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemic--when will we act? Lancet 2010; 375:1906.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Guidelines for Intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings, Geneva, 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/7\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR 2005;54(No. RR-15).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/9\">",
"      Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/10\">",
"      Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/11\">",
"      Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/12\">",
"      Sterling TR, Lau B, Zhang J, et al. Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis 2011; 204:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/13\">",
"      Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/14\">",
"      Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/15\">",
"      Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; :CD000171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/16\">",
"      Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/17\">",
"      Jordan TJ, Lewit EM, Montgomery RL, Reichman LB. Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis. JAMA 1991; 265:2987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/18\">",
"      Sterling TR, Bethel J, Goldberg S, et al. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006; 173:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/19\">",
"      Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A 2006; 103:7042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/20\">",
"      Foster S, Godfrey-Faussett P, Porter J. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. AIDS 1997; 11:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/21\">",
"      Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:S221.",
"     </a>",
"    </li>",
"    <li>",
"     Tuberculosis Prevention and Control, Public Health Agency of Canada, the Canadian Lung Association. Canadian Lung Association, 6th ed, Long RL, Ellis E.  (Eds), Public Health Agency of Canada, Toronto 2007.",
"    </li>",
"    <li>",
"     World Health Organization. WHO Three I's Meeting, World Health Organization, Geneva, 2009. p.161.",
"    </li>",
"    <li>",
"     Shwander SK, Ellner J. The human host: Immunology and susceptibility. In: Tuberculosis, 20th ed, Raviglione MC.  (Ed), Informa Healthcare, New York 2006. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/25\">",
"      Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care workers. N Engl J Med 1995; 332:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/26\">",
"      Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231.",
"     </a>",
"    </li>",
"    <li>",
"     Page KR, Godfrey-Fausset P, Chaisson RE. Tuberculosis-HIV coinfection: epidemiology, clinical aspects, and interventions. In: Reichman and Hershfield's Tuberculosis: A Comprehensive International Approach, Raviglione MC.  (Ed), Informa Healthcare, New York 2006. p.371.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/28\">",
"      Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/29\">",
"      Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/30\">",
"      Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis 1974; 110:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/31\">",
"      Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; :CD001363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/32\">",
"      Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/33\">",
"      Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 2000; 283:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/34\">",
"      Fitzgerald DW, Severe P, Joseph P, et al. No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. J Acquir Immune Defic Syndr 2001; 28:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/35\">",
"      Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1997; 337:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/36\">",
"      Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/37\">",
"      Hawken MP, Meme HK, Elliott LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997; 11:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/38\">",
"      Mohammed A, Myer L, Ehrlich R, et al. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. Int J Tuberc Lung Dis 2007; 11:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/39\">",
"      Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/40\">",
"      Rivero A, L&oacute;pez-Cort&eacute;s L, Castillo R, et al. [Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy]. Enferm Infecc Microbiol Clin 2003; 21:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/41\">",
"      Rivero A, L&oacute;pez-Cort&eacute;s L, Castillo R, et al. [Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients]. Enferm Infecc Microbiol Clin 2007; 25:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/42\">",
"      Lim HJ, Okwera A, Mayanja-Kizza H, et al. Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults. HIV Clin Trials 2006; 7:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/43\">",
"      Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982; 60:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/44\">",
"      Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365:2155.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s_cid=mm6048a3_w#Box1 (Accessed on February 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/46\">",
"      Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011; 60:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/47\">",
"      Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/48\">",
"      Soriano V, Puoti M, Garcia-Gasc&oacute; P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/49\">",
"      A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992; 145:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/50\">",
"      Villarino ME, Ridzon R, Weismuller PC, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997; 155:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/51\">",
"      Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/52\">",
"      Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/53\">",
"      Mart&iacute;nez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore) 1999; 78:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/54\">",
"      Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/55\">",
"      Lardizabal A, Passannante M, Kojakali F, et al. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/56\">",
"      Drugs for tuberculosis. Treat Guidel Med Lett 2004; 2:83.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2007. file://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm (Accessed on June 07, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/58\">",
"      Burger DM, Agarwala S, Child M, et al. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/59\">",
"      Centers for Disease Control and Prevention (CDC), American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/60\">",
"      Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA 1986; 255:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/61\">",
"      Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/62\">",
"      Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970; 26:28.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5302a6.htm (Accessed on August 29, 2011).",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/65\">",
"      Severe P, Pape J, Fitzgerald D. A randomized clinical trial of early versus standard antiretroviral therapy for HIV-infected patients with a CD4 T-cell count of 200-350 cells/mL (CIPRAHT001). Paper presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 12-15, 2009; San Francisco, CA. Abstract:H1230c.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/66\">",
"      Lawn SD, Myer L, Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/67\">",
"      Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/68\">",
"      Day JH, Charalambous S, Fielding KL, et al. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 2006; 10:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/69\">",
"      Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/12/4298/abstract/70\">",
"      Gao XF, Wang L, Liu GJ, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis 2006; 10:1080.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8011 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4298=[""].join("\n");
var outline_f4_12_4298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1862358\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107991584\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8400290\">",
"      GENERAL CONCEPTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H670905\">",
"      What is latent TB infection?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H670912\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H670608\">",
"      RISK FACTORS FOR PROGRESSION TO ACTIVE TB DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H670919\">",
"      Clinical and demographic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H670926\">",
"      HIV-related parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8400317\">",
"      RATIONALE TO TREAT LATENT TB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H670933\">",
"      Treatment of latent TB reduces active disease and transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12660510\">",
"      Interactions between HIV and tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107991598\">",
"      SCREENING FOR LATENT TB INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H670948\">",
"      Resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H670955\">",
"      Resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6036760\">",
"      CLINICAL TRIALS OF LATENT TB TREATMENT IN HIV-INFECTED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1860468\">",
"      General background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1860475\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1860610\">",
"      Botswana",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1860510\">",
"      South Africa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2403880\">",
"      North America",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1861123\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12660997\">",
"      DRUG TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12661024\">",
"      Isoniazid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12661031\">",
"      Rifamycins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12661038\">",
"      Combination regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1860402\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3356880\">",
"      General concepts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1454119\">",
"      - Efficacy versus effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1454133\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1454126\">",
"      - Data extrapolation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1861617\">",
"      Comparisons of duration of chemoprophylaxis among HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6037122\">",
"      MANAGEMENT STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1454273\">",
"      Indications for TB preventive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6037130\">",
"      Treatment regimens and duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6038924\">",
"      - Resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6038931\">",
"      - Resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6037138\">",
"      Initiation of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265621\">",
"      Assessment for TB disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H669971\">",
"      Baseline laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12662001\">",
"      Patient monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107991696\">",
"      TREATMENT OF SUSPECTED DRUG-RESISTANT LATENT TUBERCULOSIS INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6038013\">",
"      TREATMENT DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1862358\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10794?source=related_link\">",
"      Adverse effects of antiretroviral therapy in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/46/12009?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=related_link\">",
"      Monitoring the HIV-infected patient on antituberculous medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=related_link\">",
"      Rifampin and other rifamycins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39018?source=related_link\">",
"      The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=related_link\">",
"      Tuberculosis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_12_4299="Down syndrome milestones PI";
var content_f4_12_4299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differences in reaching milestones for children with Down syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Milestone",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average age of child with Down syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average age of healthy child",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sit",
"       </td>",
"       <td>",
"        11 months",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creep",
"       </td>",
"       <td>",
"        17 months",
"       </td>",
"       <td>",
"        9 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Walk",
"       </td>",
"       <td>",
"        26 months",
"       </td>",
"       <td>",
"        13 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Utter first meaningful word(s)",
"       </td>",
"       <td>",
"        18 months",
"       </td>",
"       <td>",
"        10 months",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4299=[""].join("\n");
var outline_f4_12_4299=null;
var title_f4_12_4300="Historical Pesaro results";
var content_f4_12_4300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Historical Pesaro results (transplants performed for beta thalassemia major in the 1980s and 1990s)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transplant-related mortality",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Survival",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Thalassemia-free survival",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Bu 14 + Cy 200",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        94",
"       </td>",
"       <td class=\"centered\">",
"        87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Bu 14 + Cy 200",
"       </td>",
"       <td class=\"centered\">",
"        15",
"       </td>",
"       <td class=\"centered\">",
"        84",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High (&lt;1990)",
"       </td>",
"       <td>",
"        Bu 14 + Cy 200",
"       </td>",
"       <td class=\"centered\">",
"        47",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High (&gt;1990)",
"       </td>",
"       <td>",
"        Bu 14 + Cy 120 to 160",
"       </td>",
"       <td class=\"centered\">",
"        18",
"       </td>",
"       <td class=\"centered\">",
"        79",
"       </td>",
"       <td class=\"centered\">",
"        58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult",
"       </td>",
"       <td>",
"        Bu 14 + Cy 120 to 160",
"       </td>",
"       <td class=\"centered\">",
"        34",
"       </td>",
"       <td class=\"centered\">",
"        66",
"       </td>",
"       <td class=\"centered\">",
"        62",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Risk: risk categories following the Pesaro classification.",
"    <br>",
"     High &lt;1990: high risk patients transplanted before 1990.",
"     <br>",
"      High &gt;1990: high risk patients transplanted after 1990.",
"      <div class=\"footnotes\">",
"       Bu: busulfan; Cy: cyclophosphamide.",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4300=[""].join("\n");
var outline_f4_12_4300=null;
var title_f4_12_4301="Results salv surg prost";
var content_f4_12_4301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of salvage radical prostatectomy for postradiotherapy rising PSA level",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author, year",
"       </td>",
"       <td class=\"subtitle1\">",
"        N",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median preop PSA (ng/mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median follow-up, months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organ-confined, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        SVI, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Biochemical RFS, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        CSS, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sanderson, KM; 2006",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        59*",
"       </td>",
"       <td>",
"        47 (5-yr)",
"       </td>",
"       <td>",
"        65 (10-yr)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bianco, FT; 2005",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        55 (5-yr)",
"       </td>",
"       <td>",
"        73 (10-yr)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ward, JF; 2005",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"       <td>",
"        6.4 yrs",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        58 (5-yr)",
"       </td>",
"       <td>",
"        77 (10-yr)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amling, CL; 1999",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        44 (10-yr)",
"       </td>",
"       <td>",
"        70 (10-yr)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gheiler, EL; 1998",
"       </td>",
"       <td>",
"        40&bull;",
"       </td>",
"       <td>",
"        14 (mean)",
"       </td>",
"       <td>",
"        36.1 (mean)",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        47 (5-yr)",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Garzotto, M; 1998&Delta;",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        11.8",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        69 (5-yr)",
"       </td>",
"       <td>",
"        <p>",
"         + marg: 95 (5-yr)",
"        </p>",
"        <p>",
"         - marg: 44 (5-yr)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rogers, E; 1995",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        87 (8-yr)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pontes, JE; 1993",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        12-120 (range)",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ahlering, TE; 1992",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SVI: seminal vesicle invasion; RFS: relapse-free survival; CSS: cause-specific survival; NR: not reported; + marg: surgical margins positive; - marg: surgical margins negative.",
"     <br>",
"      * Percent extraprostatic (T3/4).",
"      <br>",
"       &bull; Ten Cystoprostatectomy patients included in total.",
"       <br>",
"        &Delta; All patients also received neoadjuvant androgen deprivation therapy.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4301=[""].join("\n");
var outline_f4_12_4301=null;
var title_f4_12_4302="Management of severe asthma in children";
var content_f4_12_4302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Management of severe asthma in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 408px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IM: intramuscular; SC: subcutaneous; IV: intravenous.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Scarfone, MD, FAAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4302=[""].join("\n");
var outline_f4_12_4302=null;
var title_f4_12_4303="Jejunum adeno CA SBFT";
var content_f4_12_4303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adenocarcinoma of the jejunum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bowel follow through examination demonstrates a circumferential apple- core lesion of the jejunum (arrow), producing distension of the proximal small bowel.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_12_4303=[""].join("\n");
var outline_f4_12_4303=null;
